{
    "data": [
        {
            "id": "4876514",
            "title": "Consensus Cloud Solutions Aims For Transition, But Revenue Remains Flat",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w630\" alt=\"Digital healthcare concept with doctor updating electronic health records, showcasing health information EMR system, medical data, online documentation and patient files.\" data-id=\"2215172750\" data-type=\"getty-image\" width=\"1536\" height=\"692\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">hirun/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Investment Outlook</h2> <p><strong>Consensus Cloud Solutions (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CCSI\" title=\"Consensus Cloud Solutions, Inc.\">CCSI</a></span>)</strong> recently reported its Q4 2025 <a href=\"https://seekingalpha.com/news/4549264-consensus-cloud-solutions-beats-top-line-and-bottom-line-estimates-initiates-q1-and-fy26-outlook\">financial results</a>, beating revenue and earnings estimates.</p> <p>I previously analyzed CCSI in September 2023 with a <a href=\"https://seekingalpha.com/article/4636092-consensus-cloud-sees-slow-client-decision-making-weighing-on-growth\">Hold</a> outlook due to slow client decision-making.</p> <p>The<span class=\"paywall-full-content\"> company is executing on a transition away from its SoHo segment and focusing on its Corporate, Federal, and AI initiatives.</span></p> <p class=\"paywall-full-content\">Managing such a major shift is frequently a recipe for a prolonged period of treading water, and I remain in a ‘wait-and-see’ mode for evidence of net new growth.</p> <p class=\"paywall-full-content\">So, my outlook remains a neutral Hold.</p> <h2 class=\"paywall-full-content\">Consensus’ Market And Approach</h2> <p class=\"paywall-full-content\">Consensus Cloud Solutions provides a range of data exchange and interoperability technology services to companies in various regulated industries such as healthcare, insurance, finance, legal, manufacturing, and real estate.</p> <p class=\"paywall-full-content\">CCSI was spun off from J2 Global in 2021 as part of its effort to divide into Ziff Davis and CCSI.</p> <p class=\"paywall-full-content\">Company CEO Scott Turicchi was previously J2 Global's president and held a Managing Director position at the investment banking firm DLJ.</p> <p class=\"paywall-full-content\">CCSI's primary offerings include:</p> <ul class=\"paywall-full-content\"> <li><p>Artificial Intelligence</p></li> <li><p>Clinical Documentation</p></li> <li><p>HIPAA Compliance</p></li> <li><p>Natural Language Processing</p></li> <li><p>Interoperability</p></li> <li><p>eSignatures</p></li> <li><p>Cloud Fax</p></li> </ul> <p class=\"paywall-full-content\">The firm is shifting its focus away from legacy eFax services and towards information exchange solutions for both structured and unstructured applications.</p> <p class=\"paywall-full-content\">It has integrated generative AI technologies to help advance its transition.</p> <p class=\"paywall-full-content\">The company is also focusing more on medium and large enterprises and deemphasizing its small and home office segment.</p> <p class=\"paywall-full-content\">The pie chart below shows a breakdown of the firm’s 2025 revenue contribution, with a continued increase in the Corporate percentage:</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png\" rel=\"lightbox\" data-width=\"1264\" data-height=\"757\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w640\" alt=\"Revenue Contribution\" contenteditable=\"false\" width=\"640\" height=\"383\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-1772203875865157_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>SEC</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">To pursue new business, CCSI uses its direct sales and marketing efforts and a network of partners such as resellers, solution providers, and white-label partners.</p> <p class=\"paywall-full-content\">The global healthcare interoperability solutions market was an estimated $3.4 billion in 2023 and was forecast to reach $8.6 billion by 2030.</p> <p class=\"paywall-full-content\">If accomplished, this growth would be a CAGR of 14.2% from 2024 to 2030, a fairly robust rate of growth.</p> <p class=\"paywall-full-content\">The primary drivers for this expected growth are an increasing adoption by healthcare authorities for efficiency gains, growth in investments to enhance facilities, and a focus on patient-centric care.</p> <p class=\"paywall-full-content\">By region, North America accounted for nearly 42% of the total market share in 2023, with the hospital segment dominating demand by end-user type.</p> <p class=\"paywall-full-content\">The Asia Pacific region is expected to grow at the fastest rate of growth through 2030.</p> <p class=\"paywall-full-content\">The chart below shows the historical and projected future growth trajectory of the US healthcare interoperability solutions market through 2030:</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png\" rel=\"lightbox\" data-width=\"1166\" data-height=\"630\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w640\" alt=\"US Healthcare Interoperability Market\" contenteditable=\"false\" width=\"640\" height=\"346\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759951327_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Grand View Research</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Competitors in the healthcare interoperability market include:</p> <ul class=\"paywall-full-content\"> <li><p>Infor (Koch Industries)</p></li> <li><p>Koninklijke Philips N.V. (<a href=\"https://seekingalpha.com/symbol/PHG\" title=\"Koninklijke Philips N.V.\">PHG</a>)</p></li> <li><p>Cerner (Oracle)</p></li> <li><p>Orion Health</p></li> <li><p>NXGN Management</p></li> <li><p>OSP</p></li> <li><p>Epic Systems</p></li> <li><p><a href=\"https://visolve.com\" rel=\"nofollow\">ViSolve.com</a></p></li> <li><p>InterSystems Corporation</p></li> <li><p>INTERFACEWARE Inc.</p></li> <li><p>Jitterbit</p></li> <li><p>Veradigm (<a href=\"https://seekingalpha.com/symbol/MDRX\" title=\"Veradigm Inc.\">MDRX</a>)</p></li> </ul> <p class=\"paywall-full-content\">CCSI’s strengths include its legacy digital fax installed base in the healthcare industry and its regulatory-compliant messaging system, both of which it hopes to leverage as it shifts its focus toward interoperability functions.</p> <p class=\"paywall-full-content\">Since the company has operated at the communication layer, it has been less capital-intensive but also more modular and less structurally dominant than EHR incumbents.</p> <p class=\"paywall-full-content\">CCSI is also active in providing its solutions to other industries outside of healthcare as well as through its FedRAMP High certification.</p> <h2 class=\"paywall-full-content\">Recent Financial Trends</h2> <p class=\"paywall-full-content\">Topline revenue (blue columns) has remained essentially flat, with the most recent quarter near the midpoint of previous guidance. SoHo revenue was down 11% YoY, while corporate revenue was up 6.5%. Operating income (red line) has dipped on higher SG&amp;A expenses from incremental hiring and salary increases.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w640\" alt=\"Total Revenue and Operating Income\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038757282207_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Core operating leverage has also remained essentially flat in recent quarters.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w640\" alt=\"Degree of Operating Leverage\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038758336985_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Gross margin has proceeded with no discernible trend, but SG&amp;A has increased due to more hiring and salary increases, while R&amp;D has remained flat.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w640\" alt=\"Revenue Percentage Performance\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038759366558_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Earnings remained within the normal range for recent quarters despite slightly higher sequential SG&amp;A expenses.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w640\" alt=\"9 Quarter Earnings Per Share\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722039399208097_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">A table of various forward and trailing twelve-month metrics for CCSI is shown here for handy reference:</p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <colgroup> <col> <col> </colgroup> <tr> <td><p><strong>Metric</strong></p></td> <td><p><strong>Amount</strong></p></td> </tr> <tr> <td><p>EV/Sales - FWD</p></td> <td><p>3.0</p></td> </tr> <tr> <td><p>EV/EBITDA - FWD</p></td> <td><p>5.6</p></td> </tr> <tr> <td><p>Rev. Growth Rate Est. - FWD</p></td> <td><p>1.3%</p></td> </tr> <tr> <td><p>2026 FWD EPS Estimate</p></td> <td><p>$5.68</p></td> </tr> <tr> <td><p>Price/Sales - TTM</p></td> <td><p>1.6</p></td> </tr> <tr> <td><p>P/E GAAP - TTM</p></td> <td><p>6.81</p></td> </tr> <tr> <td><p>Revenue Growth Rate - TTM</p></td> <td><p>-0.2%</p></td> </tr> <tr> <td><p>Net Income Margin - TTM</p></td> <td><p>24.2%</p></td> </tr> <tr> <td><p>EBITDA Margin - TTM</p></td> <td><p>48.3%</p></td> </tr> <tr> <td><p>Market Capitalization</p></td> <td><p>$559,280,000</p></td> </tr> <tr> <td><p>Enterprise Value</p></td> <td><p>$1,060,000,000</p></td> </tr> <tr> <td><p>Operating Cash Flow</p></td> <td><p>$136,090,000</p></td> </tr> <tr> <td><p>EPS (Fully Diluted)</p></td> <td><p>$4.35</p></td> </tr> <tr> <td><p>Free Cash Flow per Share - TTM</p></td> <td><p>$5.50</p></td> </tr> <tr> <td><p>Seeking Alpha Quant Score</p></td> <td><p>Hold: 3.15</p></td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">(Source: Seeking Alpha)</p> <h2 class=\"paywall-full-content\">Capital Allocation</h2> <p class=\"paywall-full-content\">As of the end of 2025, CCSI had $74.7 million in cash and equivalents and $558.3 million in total debt, of which $7.0 million was due within twelve months.</p> <p class=\"paywall-full-content\">Free cash flow for the twelve months ended December 31, 2025, was $166.3 million, while stock-based compensation [SBC] was $17.7 million, leaving FCF net of SBC at $148.6 million, a strong result.</p> <p class=\"paywall-full-content\">The company is essentially a high-margin, low-growth compounder.</p> <p class=\"paywall-full-content\">Stock-based compensation [SBC] has been around 5% of revenue, which is moderate and reasonable compared to SaaS companies, which frequently award 8%–15% of revenue in SBC.</p> <p class=\"paywall-full-content\">Capex intensity is also reasonable and disciplined, leading to strong free cash flow per share ($5.50) and FCF yield of around 18%.</p> <p class=\"paywall-full-content\">The Board is offsetting SBC with net stock purchases, producing shareholder-friendly capital accretion.</p> <h2 class=\"paywall-full-content\">Why I’m Neutral On Consensus</h2> <p class=\"paywall-full-content\">Consensus is seeking to leverage its legacy eFax business into a higher growth and value-add market space of interoperability, with the healthcare industry as its primary focus.</p> <p class=\"paywall-full-content\">Management has seen hospital budgeting pause amid regulatory uncertainties, and its FedRAMP High certification appears to be driving interest from government when it isn’t shut down over political fights.</p> <p class=\"paywall-full-content\">So, CCSI has yet to produce growth in its financial results, so this narrative is primarily aspirational at this point.</p> <p class=\"paywall-full-content\">And against this is a managed decline in its SoHo segment, likely around 10% per year, so management has a significant lift just to compensate for that expected decline.</p> <p class=\"paywall-full-content\">The firm has made its AI moves for its Clarity and Harmony products for document indexing, workflow automation, and structured data extraction functions, but revenue contribution is still at an early stage for these capabilities.</p> <p class=\"paywall-full-content\">The chart below shows the frequency of various keywords with a generally negative valence in the most recent management conference call with analysts.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png\" rel=\"lightbox\" data-width=\"1200\" data-height=\"741\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w640\" alt=\"Earnings Transcript Key Terms Frequency\" contenteditable=\"false\" width=\"640\" height=\"395\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/12102811-17722038756091864_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">The graphic illustrates that Q4 2025 was the company's most challenging quarter, and its SoHo segment continues its managed decline, with headwinds from changes in the search environment negatively affecting its results.</p> <p class=\"paywall-full-content\">The SoHo decline is being managed by the company as a ‘strategic cash engine’ in order to fund its corporate channel growth efforts, and management has realigned its go-to-market approach to that end.</p> <p class=\"paywall-full-content\">Prospective investors would therefore be betting that management can ignite growth from this transition to a focus on the corporate market, Federal efforts, and its AI product initiatives.</p> <p class=\"paywall-full-content\">It’s a tall order to grow a company that is in a transition like this; many such software-based firms have languished for years making a strategic shift over time, rather than ‘ripping the bandaid off’ and jettisoning their legacy business.</p> <p class=\"paywall-full-content\">I understand management’s rationale for leveraging its legacy business to move into higher value-add and more promising market segments, but I take a ‘show me the money’ approach to these types of transitions, especially after seeing so many software companies tread water for years.</p> <p class=\"paywall-full-content\">As long as CCSI continues to integrate GenAI capabilities into its offerings wherever appropriate and remains focused on highly regulated industries like healthcare and customer segments like FedRAMP, both of which tend to be slow in adopting disruptive technologies, its revenue streams could remain less vulnerable to immediate disruption from generative AI technologies.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">However, I still remain at a neutral Hold for CCSI as I await more indications that it can restart net growth while managing its SoHo decline.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215172750/image_2215172750.jpg",
            "link": "https://seekingalpha.com/article/4876514-consensus-cloud-solutions-aims-for-transition-but-revenue-remains-flat",
            "pub_date": "2026-02-28 04:26:05",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876511",
            "title": "Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w630\" alt=\"Person administering insulin injection using a pen\" data-id=\"2195158078\" data-type=\"getty-image\" width=\"1536\" height=\"1025\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">blackCAT/E+ via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <p>Novo Nordisk (<a href=\"https://seekingalpha.com/symbol/NVO\" title=\"Novo Nordisk A/S\">NVO</a>) has experienced a hefty sell-off following worse-than-expected trial results of their weight loss drug CagriSema. Simultaneously, their main competitor, Eli Lilly (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/LLY\" title=\"Eli Lilly and Company\">LLY</a></span>), managed to keep or even expand their edge.</p> <p><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_84d767cadb48b61cfc5dc0cae214f9aa.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\" class=\"paywall-full-content\">YCharts</a></figcaption></figure><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_50a4ecd3e3870cc0afd75a40f4f77a48.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <p class=\"paywall-full-content\">I believe that this is once again a massive overreaction by the market, and here is why.</p> <h2 class=\"paywall-full-content\">What Caused The Sell-Off And Why Is It Excessive?</h2> <p class=\"paywall-full-content\">Several headlines stated that <a href=\"https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html\" rel=\"nofollow\">NVO's CagriSema failed to beat LLY's Zepbound</a>. These were based on the latest Phase III REDEFINE 4 trial results, where CagriSema (combination of semaglutide and cagrilintide) achieved an average weight loss of <a href=\"https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/2025/redefine-canadian-press-release-english.pdf\" rel=\"nofollow\">22.7% over 84 weeks</a>—compared to Zepbound's mean efficacy of <a href=\"https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-bested-by-lillys-zepbound-in-head-to-head-trial/\" rel=\"nofollow\">25.5%</a> in the same time frame. This is a miss of 280 basis points that caused Novo's stock to sell off by more than 20%.</p> <p class=\"paywall-full-content\">The market is also missing one critical detail about the trial result: Novo seems to be conservative with its dosing.</p> <p class=\"paywall-full-content\">The current clinical trial utilized a 2.4mg dose, while in contrast, Lilly achieved the higher weight loss with a dosage of 15mg. First trials already indicate that a higher dosage of 7.2mg could boost Novo's efficacy <a href=\"https://www.clinicaltrialsarena.com/news/novo-nordisks-cagrisema-bested-by-lillys-zepbound-in-head-to-head-trial/\" rel=\"nofollow\">by up to 18.3%</a>—matching or even exceeding Lilly's metrics. If we apply this improvement to the current trial, I think NVO could achieve a weight loss of 26.8% over 84 weeks.</p> <p class=\"paywall-full-content\">Novo's decision to stay at 2.4mg seems like a strategic move to prioritize safety and minimize potential side effects. While I personally like this move, I believe it should have communicated this more openly, which would have certainly helped to ease investors' concerns.</p> <p class=\"paywall-full-content\">Even if Lilly's drug will eventually come out on top, it is highly unlikely that they will manage to dominate the massive weight loss medication market—expected to reach <a href=\"https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783#:~:text=The%20global%20anti%2Dobesity%20drugs,period%20%282024%2D2032%29.\" rel=\"nofollow\">$67 billion by 2034</a>—on their own. Convenience, for example through Novo's recently approved weight loss pill, and pricing, as well as potential side effects of each drug, will certainly leave plenty of room for Novo to navigate in.</p> <p class=\"paywall-full-content\">But let's take a look at the valuation and analyze whether the data confirms my take.</p> <h2 class=\"paywall-full-content\">Valuation: Discounted Cash Flow Analysis</h2> <p class=\"paywall-full-content\">Let's first take a look at the revenue distribution of each company.</p> <p class=\"paywall-full-content\"><a href=\"https://investor.lilly.com/financial-information/quarterly-results\" rel=\"nofollow\">Eli Lilly—2025 Revenue Distribution</a></p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <colgroup> <col span=\"2\"> <col> <col> </colgroup> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. USD)</strong></td> <td><strong>Share</strong></td> </tr> <tr> <td>Diabetes Care</td> <td>34,679</td> <td>53%</td> </tr> <tr> <td>Obesity care (Zepbound)</td> <td>13,542</td> <td>21%</td> </tr> <tr> <td>Immunology</td> <td>5,247</td> <td>8%</td> </tr> <tr> <td>Neuroscience</td> <td>1,391</td> <td>2%</td> </tr> <tr> <td>Oncology</td> <td>9,376</td> <td>14%</td> </tr> <tr> <td>Other</td> <td>944</td> <td>1%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\"><a href=\"https://www.novonordisk.com/investors/financial-results.html\" rel=\"nofollow\">Novo Nordisk—2025 Revenue Distribution</a></p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. USD) </strong></td> <td><strong>Share</strong></td> </tr> <tr> <td><strong>Diabetes Care</strong></td> <td><strong>32,711</strong></td> <td><strong>67%</strong></td> </tr> <tr> <td><em>GLP-1</em></td> <td>24,039</td> <td><em>49%</em></td> </tr> <tr> <td><em>Insulin</em></td> <td>8,392</td> <td><em>17%</em></td> </tr> <tr> <td><strong>Obesity Care</strong></td> <td><strong>13,006</strong></td> <td><strong>27%</strong></td> </tr> <tr> <td><em>Wegovy</em></td> <td>12,494</td> <td><em>26%</em></td> </tr> <tr> <td><em>Saxenda</em></td> <td>512</td> <td><em>1%</em></td> </tr> <tr> <td><strong>Total Rare Diseases</strong></td> <td><strong>3,097</strong></td> <td><strong>6%</strong></td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Both companies dominate the Diabetes and Obesity Care market. According to Novo Nordisk, they currently have a global market share of 47% in the GLP-1 diabetes and obesity market.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w640\" alt=\"Novo Global GLP-1 Diabetes and Obesity Market Share\" contenteditable=\"false\" width=\"640\" height=\"532\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722032781683018.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"> </picture><figcaption><p class=\"item-caption\">Novo Global GLP-1 Diabetes and Obesity Market Share <span>(Novo Q4 Earnings)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Eli Lilly, on the other hand, published a Mounjaro (diabetes) and Zepbound (obesity) US market share of ~45% and ~60%, respectively, in their <a href=\"https://investor.lilly.com/static-files/45a92498-43d0-4e2d-a4e6-a9131841cfd6\" rel=\"nofollow\">latest earnings</a>.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png\" rel=\"lightbox\" data-width=\"1199\" data-height=\"480\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w640\" alt=\"Q4 Mounjaro US Sales and Market Share\" width=\"640\" height=\"256\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722034971841307_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Q4 Mounjaro US Sales and Market Share <span>(Lilly Q4 Earnings)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png\" rel=\"lightbox\" data-width=\"1197\" data-height=\"474\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w640\" alt=\"Q4 Zepbound US Sales and Market Share\" width=\"640\" height=\"253\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722035625468833_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Q4 Zepbound US Sales and Market Share <span>(Lilly Q4 Earnings)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">In terms of revenue and market share, the companies appear to be fairly evenly matched in these two key markets, but how is this reflected in the current valuation?</p> <p class=\"paywall-full-content\">For our valuation model, we first need some general assumptions.</p> <h2 class=\"paywall-full-content\"> </h2> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Metric</strong></td> <td><strong>Eli Lilly</strong></td> <td><strong>Novo Nordisk</strong></td> </tr> <tr> <td>EBIT Margin</td> <td>Current rate of 46%</td> <td>Average of the last 4 years: 44%</td> </tr> <tr> <td>Cash Conversion</td> <td>The best rate of the last 4 years: 2022: 57%</td> <td>Average of the last 4 years:76%</td> </tr> <tr> <td>WACC</td> <td colspan=\"2\">9%</td> </tr> <tr> <td>Perpetuity Growth</td> <td colspan=\"2\">3.5%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <h4 class=\"paywall-full-content\">Required Growth</h4> <p class=\"paywall-full-content\">Out of these assumptions and the current market caps, we can calculate the required growth rate needed to justify the current valuation for each company.</p> <h5 class=\"paywall-full-content\">Eli Lilly</h5> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987924276133_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Required Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721987926552494_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Required Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Considering our assumptions, Eli Lilly needs to achieve an average growth rate of 21.7% per year for the next eight years to justify their current market cap of $913 billion.</p> <h5 class=\"paywall-full-content\">Novo Nordisk</h5> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988019426782_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Required Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Required Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988022840123_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Required Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Novo Nordisk, on the other hand, needs no additional growth for the featured time frame to justify their current valuation.</p> <p class=\"paywall-full-content\">But like mentioned before, the market is currently expecting Lilly to outgrow Novo in the next few years, so let's try to incorporate this into the valuation models.</p> <h4 class=\"paywall-full-content\">Realistic Growth</h4> <p class=\"paywall-full-content\">To get realistic growth rates for Lilly, I weighted the expected market growth rate of each business segment with the current revenue share.</p> <h5 class=\"paywall-full-content\">Eli Lilly</h5> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <colgroup> <col span=\"2\"> <col> <col> </colgroup> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. USD)</strong></td> <td><strong>Share</strong></td> <td><strong>Expected Market CAGR</strong></td> </tr> <tr> <td>Diabetes Care</td> <td>34,679</td> <td>53%</td> <td><a href=\"https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570#:~:text=KEY%20MARKET%20INSIGHTS&amp;text=The%20global%20diabetes%20drugs%20market,12.7%25%20during%20the%20forecast%20period.\" rel=\"nofollow noopener\">12%</a></td> </tr> <tr> <td>Obesity care (Zepbound)</td> <td>13,542</td> <td>21%</td> <td><a href=\"https://www.fortunebusinessinsights.com/anti-obesity-drugs-market-104783#:~:text=The%20global%20anti%2Dobesity%20drugs,period%20%282024%2D2032%29.\" rel=\"nofollow noopener noopener noopener\">29%</a></td> </tr> <tr> <td>Immunology</td> <td>5,247</td> <td>8%</td> <td><a href=\"https://www.precedenceresearch.com/immunology-market#:~:text=The%20global%20immunology%20market%20size,10.20%25%20from%202025%20to%202034.\" rel=\"nofollow noopener\">10%</a></td> </tr> <tr> <td>Neuroscience</td> <td>1,391</td> <td>2%</td> <td><a href=\"https://www.grandviewresearch.com/industry-analysis/neuroscience-market#:~:text=The%20global%20neuroscience%20market%20size,5.56%25%20from%202023%20to%202030.\" rel=\"nofollow noopener\">5%</a></td> </tr> <tr> <td>Oncology</td> <td>9,376</td> <td>14%</td> <td><a href=\"https://www.towardshealthcare.com/insights/immuno-oncology-drugs-market-sizing#:~:text=The%20global%20immuno%2Doncology%20drugs,16.34%25%20between%202025%20and%202034.\" rel=\"nofollow noopener\">16%</a></td> </tr> <tr> <td>Other</td> <td>944</td> <td>1%</td> <td>0%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Weighted Anticipated Growth: 15.6%</p> <p class=\"paywall-full-content\">If we apply this expected growth rate to our DCF, Eli Lilly seems to currently be overvalued by up to 32%.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-1772198825243967_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w640\" alt=\"Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"true\" data-width=\"640\" data-height=\"251\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17722053680982301_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Eli Lilly Discounted Cash Flow Analysis - Realistic Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <h5 class=\"paywall-full-content\">Novo Nordisk</h5> <p class=\"paywall-full-content\">To reflect the current pessimism, I assumed no growth at all for the obesity division in the first scenario of Novo. Additionally, I also only expected a growth rate of 10% in the Diabetes segment—compared to the expected market rate of 12%.</p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. DKK)</strong></td> <td><strong>Share</strong></td> <td><strong> Anticipated CAGR </strong></td> </tr> <tr> <td>Diabetes Care</td> <td>207,109</td> <td>67%</td> <td><p>10%</p></td> </tr> <tr> <td>Obesity Care</td> <td>82,347</td> <td>27%</td> <td>0%</td> </tr> <tr> <td>Total Rare Diseases</td> <td>19,608</td> <td>6%</td> <td>0%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Weighted Anticipated Growth: 6.7%</p> <p class=\"paywall-full-content\">Even with these rather conservative assumptions, Novo Nordisk seems to currently be undervalued by up to 60%.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988354434044_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988356880953_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (II) <span>(own assumptions)</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For our second scenario and as our \"Bull-Case\" for Novo Nordisk, I anticipated an Obesity Care growth rate of 10% p.a.—still only 1/3 of the expected market rate.</p> <div class=\"table-responsive paywall-full-content\"> <span class=\"sa-table-scroll-wrapper sa-hide-scrollbar\"><span data-intersection-boundary=\"start\" data-test-id=\"table-scroll-wrapper-boundary-start\"></span><table> <tr> <td><strong>Segment</strong></td> <td><strong>Revenue (mill. DKK)</strong></td> <td><strong>Share</strong></td> <td><strong> Anticipated CAGR </strong></td> </tr> <tr> <td>Diabetes Care</td> <td>207,109</td> <td>67%</td> <td><p>10%</p></td> </tr> <tr> <td>Obesity Care</td> <td>82,347</td> <td>27%</td> <td>10%</td> </tr> <tr> <td>Total Rare Diseases</td> <td>19,608</td> <td>6%</td> <td>0%</td> </tr> </table> <span data-intersection-boundary=\"end\" data-test-id=\"table-scroll-wrapper-boundary-end\"></span></span><button type=\"button\" class=\"sa-table-enlarge-button\">Click to enlarge</button> </div> <p class=\"paywall-full-content\">Weighted Anticipated Growth: 9.4%</p> <p class=\"paywall-full-content\">With these growth rates, the potential upside improves to up to 92% for Novo Nordisk.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"753\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (I)\" width=\"640\" height=\"126\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420342872_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (III) <span>(own assumptions)</span></p></figcaption></figure><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png\" rel=\"lightbox\" data-width=\"3822\" data-height=\"1500\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w640\" alt=\"Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (IV)\" width=\"640\" height=\"251\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/51058349-17721988420844944_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\">Novo Nordisk Discounted Cash Flow Analysis - Realistic Growth (IV) <span>(own assumptions)</span></p></figcaption></figure></p> <h2 class=\"paywall-full-content\">Risks To Consider</h2> <p class=\"paywall-full-content\">Like mentioned above, the weight loss market is expected to reach a TAM of $67 billion by 2034. This will certainly lead to competitors vying for market share in the future. Any breakthrough drug by competition could destroy the duopoly between Novo and Lilly and, in turn, damage the top- and bottom-line for both companies.</p> <p class=\"paywall-full-content\">While these new drugs are screened heavily before approval, potential long-term and rare side effects are hard to detect. They are now used by millions of people for the first time, which might lead to unexpected complications.</p> <p class=\"paywall-full-content\">As shown in the revenue table, both companies, but especially Novo, are very reliant on their GLP-1 medication. Should any regulatory change or a safety concern emerge with this drug type in particular, Novo would be impacted more than diversified peers.</p> <h2 class=\"paywall-full-content\">Conclusion</h2> <p class=\"paywall-full-content\">The valuation gap between Lilly and Novo is an exaggeration. Novo appears to be significantly undervalued, whereas Lilly appears to be priced for perfection right now, even after using more optimistic assumptions for Lilly and conservative ones for Novo.</p> <p class=\"paywall-full-content\">At current prices, Novo Nordisk is a Strong Buy. Their dominant position in the Diabetes market alone justifies higher valuations. This, paired with the still promising Obesity market as well as a potential undervaluation of up to 92%, makes it a compelling pick right now.</p> <p class=\"paywall-full-content\">Eli Lilly is a high-quality company that is very well positioned to benefit from the growing obesity market. Their other segments—especially Oncology and Immunology—also seem promising. At current prices, I, however, believe that there are better opportunities in the market, which is why I rate Lilly a Hold.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195158078/image_2195158078.jpg",
            "link": "https://seekingalpha.com/article/4876511-eli-lilly-vs-novo-nordisk-the-valuation-gap-is-unreasonable",
            "pub_date": "2026-02-28 04:20:57",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876510",
            "title": "CoreWeave: From Growth Story To Capital Story",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w630\" alt=\"Data Center Server Racks with Purple Neon Lights in Dark Room\" data-id=\"2254337477\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">asbe/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Investment Thesis</h2> <p>CoreWeave, Inc. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CRWV\" title=\"CoreWeave, Inc.\">CRWV</a></span>) just had one of the best infrastructure growth quarters in cloud history, growing revenues by 110% and growing its backlog to $66.8 billion. Even though CRWV is down since my <a href=\"https://seekingalpha.com/article/4863334-why-coreweave-suddenly-de-risked\" class=\"paywall-full-content\">last coverage</a><span class=\"paywall-full-content\">, the post-earnings </span><a href=\"https://seekingalpha.com/news/4558575-biggest-stock-movers-friday-nflx-xyz-dell-and-more\" class=\"paywall-full-content\">drop</a><span class=\"paywall-full-content\"> is not due to weakening demand but due to the magnitude of the required CapEx in 2026 and the rise in interest expense, which has changed the narrative from a growth play to a capital allocation play.</span></p> <p class=\"paywall-full-content\">The fundamentals are still very favorable if management can successfully execute on improving margins and converting the backlog. This is a high-upside AI infrastructure compounder, but the key now is the timing and the <a href=\"https://seekingalpha.com/symbol/CRWV/balance-sheet\">balance sheet</a>.</p> <p class=\"paywall-full-content\"><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0e7cd207272d5e7b08c2214ba26ee92f.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <h2 class=\"paywall-full-content\">From Backlog Euphoria to Balance Sheet Reality</h2> <p class=\"paywall-full-content\">CoreWeave’s Q4 earnings were the type of report that can be considered technically strong but also emotionally uncomfortable at the same time. They beat with <a href=\"https://seekingalpha.com/news/4558179-coreweave-gaap-eps-of-0_89-misses-by-0_21-revenue-of-1_57b-beats-by-40m\">$1.572 billion</a> of revenue, up 110% YoY, and extended their contracted revenue backlog to <a href=\"https://static.seekingalpha.com/uploads/sa_presentations/248/123248/original.pdf\">$66.8 billion</a>.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png\" rel=\"lightbox\" data-width=\"2048\" data-height=\"1105\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w640\" alt=\"CRWV\" width=\"640\" height=\"345\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868655569086_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Earnings Q4 2025</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">In any other growth story, these two numbers would settle any debate. Yet the stock went down, and I understand why. When a company commits to at least <a href=\"https://seekingalpha.com/article/4875914-coreweave-inc-crwv-q4-2025-earnings-call-transcript\">$30-$35 billion</a> of Capex spending in 2026 while also posting a $452 million GAAP net loss in one quarter, the conversation stops being about the demand curve and starts becoming about the financing curve.</p> <p class=\"paywall-full-content\">My view is quite simple, uncomfortable but very investable if one accepts it. CoreWeave is not being valued on the size of the AI industry. It is being valued on whether it can keep its hypergrowth synchronized with the cost of capital. And today, the market is implying a non-trivial probability that the former will not be synchronized with the latter.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png\" rel=\"lightbox\" data-width=\"2048\" data-height=\"1106\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w640\" alt=\"CRWV\" width=\"640\" height=\"346\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-1772186865628448_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Earnings Q4 2025</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">With regard to operating, the company is continuing to operate as a company that found a rare pocket of structural scarcity. The revenue growth came in at $5.13 billion, growing 168% year-over-year, which is one of the faster growth stories we've seen for infrastructure growth in the public markets.</p> <p class=\"paywall-full-content\">The revenue guide for Q1 of $1.9-$2.0 billion and for FY26 of $12-$13 billion indicates that the flywheel is continuing to go, although slightly softer than investors might have wanted at mid-point. This is not a demand story. In fact, the demand story that came out of the call yesterday was almost ridiculously confident. Virtually sold out for 2026 capacity, stable prices, and selling old-generation GPUs into inference ahead of the arrival of the newer generation.</p> <p class=\"paywall-full-content\">The not-so-understood factor is the way that CoreWeave is going about growing that number. In Q4 alone, the company added around 260MW of active power, bringing the total to <a href=\"https://static.seekingalpha.com/uploads/sa_presentations/248/123248/original.pdf\">over 850MW</a> active, with over 3.1 GW contracted. This isn’t a growth rate; it’s a sprint where the company is continuously adding capacity, then correctly pointing out that revenue monetization takes a little longer as the work ramps up and contract revenue recognition comes online. In other words, the operational win of Q4 is the seed of the guided trough of Q1.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png\" rel=\"lightbox\" data-width=\"2048\" data-height=\"1137\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w640\" alt=\"CRWV\" width=\"640\" height=\"355\" contenteditable=\"false\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/49853134-17721868658756926_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span><figcaption><p class=\"item-caption\"><span>Earnings Q4 2025</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">This isn’t a mistake; it’s the business model. I think the lazy assumption that investors make is that backlog equals safety. Backlog is good; it’s not the same as liquidity or certainty of timing. A $66.8 billion backlog with a significant percentage of that backlog extending beyond 24 months is a phenomenal position, but it also creates a subtle pitfall where the market assumes that a long-dated demand asset is, in fact, a short-dated cash asset.</p> <p class=\"paywall-full-content\">This isn’t something that CoreWeave’s equity can afford to misunderstand, as the cost structure is up-front and heavily weighted, reflected in a balance sheet that now tops $49.3 billion in total assets, driven by $30.6 billion of property and equipment.</p> <h2 class=\"paywall-full-content\">The Interest Meter Is Now the Real Earnings Story</h2> <p class=\"paywall-full-content\">CoreWeave’s soft quarter wasn’t driven by demand but rather by how the company is choosing to finance it. Revenue grew 110% year over year, while adjusted EBITDA came in at $898 million, affirming the strength of the economics of core compute. However, the real news is hiding below the operating line, where interest expense grew to $388 million in Q4 and $1.23 billion for the year, while the Q1 guide implies an even higher growth rate.</p> <p class=\"paywall-full-content\">The way I approach the stock is now different. The issue is that the company is funding its growth with a rising debt stack at an increasing rate. The company now has greater than $18 billion in total debt, and the leverage is now impacting the timing risk. Their view is Q1 is the margin trough, and the ramp in new capacity and the ramp in revenue are post-Q1. That’s a reasonable view. The question is, as an investor, is the execution speed keeping pace with the financing speed?</p> <p class=\"paywall-full-content\"><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_29baece6b9fa7333e7aa8d3b5febd055.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <h2 class=\"paywall-full-content\">Valuation: The Market Is Pricing in Execution, Not Perfection</h2> <p class=\"paywall-full-content\">Consensus revenue estimates have now projected revenue of $12.05 billion in 2026 and <a href=\"https://seekingalpha.com/symbol/CRWV/earnings/estimates\">$19.86 billion</a> in 2027, suggesting forward multiples of 4x sales in 2026 but compressing to 2.6x sales in 2027 and less than 2x sales in 2028. At a high level, the forward multiples appear relatively cheap for a company growing its revenue at triple digits in the near future.</p> <p class=\"paywall-full-content\">The problem is valuation multiples can't be analyzed in isolation. EV is highly levered due to over $18 billion in debt, which means EV to revenue is actually looking more like infrastructure multiples rather than cloud multiples. If they're able to execute and drive 25-30% operating margins from this backlog over time, then these types of multiples could actually prove to be pretty conservative.</p> <p class=\"paywall-full-content\"><figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_0f44388a295db1d190a3d547bda74453.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\">YCharts</a></figcaption></figure></p> <h2 class=\"paywall-full-content\">The Capital Structure Is the Single Point of Failure</h2> <p class=\"paywall-full-content\">The main risk is not related to demand, competition, or customer concentration but rather to financial leverage and timing. CoreWeave closed 2025 with more than $18 billion of debt on its balance sheet, FY interest expense of $1.23 billion, and Q1 2026 interest guidance towards a $2 billion+ annualized run rate (guidance <a href=\"https://seekingalpha.com/article/4875914-coreweave-inc-crwv-q4-2025-earnings-call-transcript\">$510-$590 million</a>). At the same time, 2026 Capex is projected to be $30-$35 billion.</p> <p class=\"paywall-full-content\">Depreciation and power costs are incurred immediately, while revenue growth is a function of time. As a result, there is a built-in margin compression during growth phases. This is a balance sheet-based model, and execution needs to be perfect for leverage to work for shareholders rather than against them.</p> <h2 class=\"paywall-full-content\">Takeaway</h2> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">CoreWeave isn’t being evaluated based on the demand for AI anymore; it’s being evaluated based on capital discipline. If the management team is successful in turning the backlog into cash flow, with leverage management, the potential upside is large. This is a conviction story, but the position size depends upon the sensitivity of the balance sheet.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2254337477/image_2254337477.jpg",
            "link": "https://seekingalpha.com/article/4876510-coreweave-from-growth-story-to-capital-story",
            "pub_date": "2026-02-28 04:11:43",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876499",
            "title": "LeMaitre Vascular: The Compounder Keeps Compounding",
            "description": "<figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://media.gettyimages.com/id/2194227950/photo/red-heart-and-stethoscope-lying-on-euro-banknotes-illustrating-expensive-healthcare-or.jpg?b=1&amp;s=612x612&amp;w=0&amp;k=20&amp;c=CCi9-oDsnyaDgs2604xYctYgsAmCAUEt_ihHrCBJV9s=\" alt=\"Red heart and stethoscope lying on euro banknotes illustrating expensive healthcare or healthy investment\" data-id=\"2194227950\" data-type=\"getty-image\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Alberto Marrupe Gutierrez/iStock via Getty Images</p></figcaption></figure><div class=\"inline_ad_placeholder\"></div> <p data-eci=\"true\">I last covered LeMaitre Vascular (<span class=\"ticker-hover-wrapper\">NASDAQ:<a href=\"https://seekingalpha.com/symbol/LMAT\" title=\"LeMaitre Vascular, Inc.\">LMAT</a></span>) at $81 <a href=\"mailto:https://seekingalpha.com/article/4795377-lemaitre-vascular-scaling-nicely-as-global-demand-builds\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/article/4795377-lemaitre-vascular-scaling-nicely-as-global-demand-builds\" target=\"_blank\">in June 2025</a>, reiterating my Buy rating. Eight months later, shares are up about 35%, more than double that of the broader market. The stock jumped ~20% alone on the recent Q4 beat and raise, with 2026<span class=\"paywall-full-content\"> guidance coming in 13% above Wall Street’s consensus. Pricing power, operating leverage, and international growth were all contributors.</span></p> <p class=\"paywall-full-content\">LMAT has been one of the top performers in my own portfolio over this period. Is it time to trim? Is there still near-term upside for those looking to add shares?</p> <p class=\"paywall-full-content\">Having digested the 2025 results, my short answer is that the business has earned its high valuation multiples. A key catalyst is Artegraft – the international rollout is changing the math. But a more important takeaway is that LMAT’s overall earnings power appears to have stepped higher. This is structural rather than cyclical.</p> <h2 class=\"paywall-full-content\">Q4 and Full-Year 2025: Another Clean Sheet</h2> <p class=\"paywall-full-content\">The <a href=\"mailto:https://seekingalpha.com/pr/20414156-lemaitre-q4-2025-financial-results\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/pr/20414156-lemaitre-q4-2025-financial-results\" target=\"_blank\">latest quarterly report</a> exceeded expectations in almost every way. Sales were up 16% YoY with organic growth at 15%. All segments gained, led by grafts (27%), valvulotomes (20%), and carotid shunts (18%). Growth was also broad-based geographically, with EMEA up 29%, APAC 20%, and the Americas 10%. Profitability metrics were also outstanding across the board. Organic growth in Q4 broke down to about 9% price and 6% unit growth, meaning the recent margin expansion isn’t just due to volume.</p> <p class=\"paywall-full-content\">Most important is that this has been a pattern. For several years LMAT has been growing sales by double digits while managing gross margins of 60-70%.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png\" rel=\"lightbox\" data-width=\"1432\" data-height=\"427\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w640\" alt=\"Bar graph showing gross profit growth for LMAT over the past decade.\" contenteditable=\"false\" width=\"640\" height=\"191\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013010596_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (LMAT Financials - Gross Profit)</span></p></figcaption></figure><p class=\"paywall-full-content\">The FY 2025 results included beats on revenue and EPS. The $2.91 (midpoint) guidance for 2026 represents an 11.5% increase.</p> <h2 class=\"paywall-full-content\">The Artegraft Surprise</h2> <p class=\"paywall-full-content\">For me, the most important news in this report wasn’t the headline figures. It was buried <a href=\"mailto:https://seekingalpha.com/article/4875065-lemaitre-vascular-inc-lmat-q4-2025-earnings-call-transcript\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/article/4875065-lemaitre-vascular-inc-lmat-q4-2025-earnings-call-transcript\" target=\"_blank\">in the earnings call Q&amp;A</a>.</p> <p class=\"paywall-full-content\">Management said the addressable market for Artegraft outside the U.S. may be much larger than previously understood. LMAT originally sold Artegraft in the U.S. for dialysis access procedures. The procedure is handled differently in Europe: patients skip the implanted graft step entirely and go straight to catheters. That creates an opportunity to develop new demand rather than simply substitute for existing procedures. As adoption has progressed, Artegraft is also being used in leg bypass procedures in addition to dialysis access.</p> <p class=\"paywall-full-content\">From a profitability standpoint, this fits well with LMAT’s “mix shift” toward biologic implants, which now account for more than half of total sales. These products tend to have higher average selling prices and attractive margins. As a result, Artegraft should disproportionately help earnings growth even if the impact on the top line is modest.</p> <p class=\"paywall-full-content\">2025 international sales of Artegraft came in at $4M versus guidance of $2M, and that’s expected to grow to $10M in 2026. Approvals are in place for 52 countries, with traction gaining in Germany, Austria, Switzerland, and the Netherlands. The U.K. and parts of southern Europe are just getting started.</p> <p class=\"paywall-full-content\">In short, this product is performing much better than management previously modeled. The markets are larger than anticipated, and there appears to be a long runway ahead. It’s a meaningful development for long-term LMAT investors and one I’ll watch closely this year.</p> <h2 class=\"paywall-full-content\">Balance Sheet and Capital Allocation for LMAT</h2> <p class=\"paywall-full-content\">LMAT ended 2025 with a net cash position of about $190M, accounting for its $168M in convertible notes. This is a significant war chest for a company with a ~$2.5B market cap. M&amp;A, as always, is on the table for LMAT. Management has identified a number of potential targets in both vascular and cardiac surgery.</p> <p class=\"paywall-full-content\">The board approved a <a href=\"mailto:https://seekingalpha.com/news/4557368-lemaitre-vascular-raises-dividend-by-25-to-025\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/news/4557368-lemaitre-vascular-raises-dividend-by-25-to-025\" target=\"_blank\">25% dividend increase</a> for Q1 2026, making it fifteen consecutive years of increases. A new $100M share repurchase authorization was also approved. Neither makes LMAT an “income” play, but they do add to total return.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png\" rel=\"lightbox\" data-width=\"1431\" data-height=\"355\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w640\" alt=\"Table showing dividend data for LeMaitre Vascular\" contenteditable=\"false\" width=\"640\" height=\"159\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-1772216013065088_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (February 27, 2026)</span></p></figcaption></figure><h2 class=\"paywall-full-content\">LMAT: Valuation and Updated Price Target</h2> <p class=\"paywall-full-content\">Here’s the tension: the stock has appreciated by ~35% since last summer, and Wall Street’s consensus price target shows no near-term upside. The market appears to have priced in a lot of good news.</p> <p class=\"paywall-full-content\">My preferred method of assessing valuation is to compare companies to their recent historical averages. Given LMAT’s niche direct-to-hospital model and biologics-heavy mix, its own history is more informative than comparing it to the much larger, diversified medtech conglomerates. (Broad sector comparisons are even less helpful – particularly in Health Care where the business models of insurers, drug makers, and equipment manufacturers are vastly different.)</p> <p class=\"paywall-full-content\">By those measures, LMAT is trading in line <a href=\"mailto:https://seekingalpha.com/symbol/LMAT/valuation/metrics\" rel=\"nofollow\" title=\"mailto:https://seekingalpha.com/symbol/LMAT/valuation/metrics\" target=\"_blank\">with its own norms</a>: slightly lower in P/E, about even in EV/EBITDA, and slightly higher in EV/sales.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png\" rel=\"lightbox\" data-width=\"1431\" data-height=\"552\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w640\" alt=\"Table comparing current valuation data for LMAT against historical averages.\" contenteditable=\"false\" width=\"640\" height=\"247\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160132261205_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (data compiled by the author on February 27, 2026)</span></p></figcaption></figure><p class=\"paywall-full-content\">Assuming the current P/E of 40x holds for the next couple of years, we’re looking at price targets of roughly $116 for 2026, $124 for 2027, and $134 for 2028. This is a CAGR of ~7.5%, or just over 8% annually including the dividend.</p> <p class=\"paywall-full-content\">I find this conservative given the growth rates outlined above, particularly with the potential bottom-line impact of Artegraft adoption in Europe. Positive reversion to the 45x multiple would add another ~12% upside.</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png\" rel=\"lightbox\" data-width=\"1431\" data-height=\"263\" data-og-image-twitter_small_card=\"false\" data-og-image-twitter_large_card=\"false\" data-og-image-twitter_image_post=\"false\" data-og-image-msn=\"false\" data-og-image-facebook=\"false\" data-og-image-google_news=\"false\" data-og-image-google_plus=\"false\" data-og-image-linkedin=\"false\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w640\" alt=\"Table providing EPS estimates for LMAT through 2028.\" contenteditable=\"false\" width=\"640\" height=\"118\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/58879822-17722160131071455_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha (data compiled by the author on February 27, 2026)</span></p></figcaption></figure><p class=\"paywall-full-content\">My current view: for those already holding LMAT, there’s no reason to sell. The intrinsic value is moving higher, and its operating leverage is among the industry leaders. But clearly for new investors, the entry point is less attractive than it was this time last year (based on what we knew then). The premium relative to peers like Boston Scientific (<a href=\"https://seekingalpha.com/symbol/BSX\" title=\"Boston Scientific Corporation\">BSX</a>), Stryker (<a href=\"https://seekingalpha.com/symbol/SYK\" title=\"Stryker Corporation\">SYK</a>), and Medtronic (<a href=\"https://seekingalpha.com/symbol/MDT\" title=\"Medtronic plc\">MDT</a>) stands out, though I believe it’s justified given LMAT’s niche focus. A pullback below $100 would improve the overall risk-reward dynamic.</p> <h2 class=\"paywall-full-content\">Bottom Line: Buy Rating Reiterated</h2> <p class=\"paywall-full-content\">LeMaitre Vascular is doing what it’s been doing for years: growing sales while maintaining pricing power and expanding internationally. The Artegraft surprise is the latest reason to believe earnings have room to grow beyond the base case.</p> <p class=\"paywall-full-content\">I’m raising my price target for year-end 2026 to $116-$130 based on a forward PE of 40-45x. I maintain a <em>Buy</em> rating for long-term investors. The potential upside (at present) may be less attractive than a year ago, but LMAT remains an excellent candidate for a dividend growth portfolio. The main questions remain: (1) Can LMAT continue to raise prices without softening demand? (2) Can management sustain gross margins in the low-70% range? (3) Can the company continue expanding its direct sales model internationally given the upfront costs and regulatory challenges?</p> <p class=\"paywall-full-content\">On all three counts, 2025 was certainly encouraging.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">Author’s Note: This analysis reflects data and information available as of February 27, 2026.</p>",
            "image": null,
            "link": "https://seekingalpha.com/article/4876499-lemaitre-vascular-the-compounder-keeps-compounding",
            "pub_date": "2026-02-28 04:01:27",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876493",
            "title": "Dell Is Now Deep In Bargain Territory (Rating Upgrade)",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w630\" alt=\"Dell Technologies sign on the top of he building. Dell Technologies Inc. is an American multinational technology company.\" data-id=\"2238577123\" data-type=\"getty-image\" width=\"1536\" height=\"1022\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Stefan Sutka/iStock Editorial via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <figure class=\"regular-img-figure a-r paywall-full-content\" contenteditable=\"false\"><picture> <img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-1772207822623405.png?io=w640\" alt=\"Rating History\" width=\"293\" height=\"417\" contenteditable=\"false\" data-width=\"293\" data-height=\"417\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-1772207822623405.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure> <p>Back in January, I <a href=\"https://seekingalpha.com/article/4858671-dell-is-approaching-bargain-territory\">stated that</a> Dell Technologies Inc. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/DELL\" title=\"Dell Technologies Inc.\">DELL</a></span>) stock was approaching bargain territory. With AI server demand being robust, their backlog growing in a strong manner, and a valuation<span class=\"paywall-full-content\"> that was well below the IT sector median, I believed the risk/reward was highly attractive. While the stock remained muted for a period after my update, Dell has soared after they reported </span><a href=\"https://investors.delltechnologies.com/static-files/cbb4c668-2613-4d5c-a7dc-98fe4592b5a5\" rel=\"nofollow\" class=\"paywall-full-content\">their most recent earnings</a><span class=\"paywall-full-content\"> just yesterday (Feb 26th) after market close. As you can see on the right, this brings the stock's gains to over 20% since the publication of my previous article. Today I'll be providing an earnings review to see whether the current state of things still offers investor opportunity.</span></p> <p class=\"paywall-full-content\">In the below analysis, it is shown that Dell's results are generally strong even if there are some challenges and risks present. Guidance is shown to be solid, and with the forward P/E ratio having contracted since my previous article, I would say that Dell stock has in fact moved deeper into bargain territory despite the post-earnings rally. Therefore, I have decided to upgrade to a Strong Buy rating.</p> <h2 class=\"paywall-full-content\">FY2026 Q4 Overview</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure a-c paywall-full-content\" contenteditable=\"false\"><picture> <img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722083355748675.png?io=w640\" alt=\"Overview\" contenteditable=\"false\" width=\"589\" height=\"205\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722083355748675.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722083355748675.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722083355748675.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"> </picture><figcaption><p class=\"item-caption\"><span>Dell Q4 Presentation</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Let's start off with an overview of the company's financial performance for FY2026 Q4. Firstly, for the top line, Dell reported $33.4 billion in revenues, up 39% YoY. This is a clear improvement from the <a href=\"https://investors.delltechnologies.com/static-files/76df3c58-df57-458a-b91c-3869487a92a2\" rel=\"nofollow\">previous quarter's growth rate</a> of just 11%, and so there has been a very meaningful pickup in business momentum overall. We'll go into more depth for their two segments later, but it should be noted that both Infrastructure Solutions Group and Client Solutions Group saw acceleration, and so there has been broad improvement in the company's trajectory. Lastly, note that Dell <a href=\"https://seekingalpha.com/symbol/DELL/earnings\">posted a monster beat</a> of top line expectations as they surpassed estimates by $1.75 billion as a statement of outperformance in the quarter.</p> <p class=\"paywall-full-content\"><a href=\"https://investors.delltechnologies.com/static-files/433e7b1b-c749-4411-bcd7-2f23fbf7f112\" rel=\"nofollow\">Above, you can see that</a> non-GAAP operating income grew slower than the top line as a signal of margin weakness. If you go and take a look at their Q4 earnings release, you'll see that adjusted gross margin dropped by nearly 4 percentage points. This could be a signal of consumers choosing lower margin products or higher costs affecting their Client Solutions Group and AI-server commoditization headwinds in their Infrastructure Solutions Group. In both segments, operating income growth underperformed revenue increases. While this is unfavorable, Dell did control their operating expenses well. Non-GAAP operating expenses as a percentage of revenue dropped by 3.2 percentage points as a sign of good efficiency, but the adjusted operating margin still dipped due to the gross margin weakness.</p> <p class=\"paywall-full-content\">At the end of the day, Dell actually still managed a strong bottom line growth rate. For adjusted EPS, they reported $3.89, representing a 45% increase YoY. This also beat expectations, as they surpassed consensus estimates by $0.38. Also, note that there has been a considerable speedup of growth from 20% back in Q3. In FY2026, the company did a total of $6.014 billion in share repurchases, and so that definitely played a part in boosting the EPS figure. Investors should be encouraged by the amount of capital returns they are seeing.</p> <p class=\"paywall-full-content\">For Q4 specifically, stock buybacks are up from $734 million to $1.847 billion YoY, and so the company is sharing their strong cash flows with shareholders. As a whole, I consider Dell's company-wide financial performance to be robust even if gross margin was a sore point.</p> <h2 class=\"paywall-full-content\">Infrastructure Solutions Group</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722096913620455_origin.png\" rel=\"lightbox\" data-width=\"827\" data-height=\"509\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722096913620455_origin.png?io=w640\" alt=\"ISG\" width=\"640\" height=\"394\" contenteditable=\"false\" data-width=\"640\" data-height=\"394\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722096913620455_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722096913620455_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722096913620455_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722096913620455_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Dell Q4 Presentation</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For their all-important ISG, Dell saw explosive revenue growth of 73% YoY, and you can see that this is a major acceleration of growth. This signals strong AI tailwinds and robust business momentum, but as mentioned earlier, margin is under a bit of pressure, and that could be a result of AI-server commoditization risks. Investors should definitely monitor margin for ISG moving forward, as contraction could take a major bite out of their profitability. Note that while revenue growth is far stronger than in the year ago quarter, operating income growth is actually slower, and at the end of the day, profits matter more.</p> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure a-c paywall-full-content\" contenteditable=\"false\"><picture> <img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-1772210093129191.png?io=w640\" alt=\"ISG Metrics\" contenteditable=\"false\" width=\"612\" height=\"351\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-1772210093129191.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-1772210093129191.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-1772210093129191.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"> </picture><figcaption><p class=\"item-caption\"><span>Dell Q4 Presentation</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For demand, there are really no signs of a slowdown at this point. Some worry that CAPEX will drop, but in the most recent earnings season, it seems hyperscalers are actually deciding to spend more. As you can see above, orders exploded and are up by ~1900% YoY. Furthermore, you can see that their backlog is now $43 billion after a ~950% increase YoY. These are truly eye-popping numbers and provide key reassurance that demand remains through the roof right now.</p> <h2 class=\"paywall-full-content\">Client Solutions Group</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722104439629803_origin.png\" rel=\"lightbox\" data-width=\"802\" data-height=\"513\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722104439629803_origin.png?io=w640\" alt=\"CSG\" width=\"640\" height=\"409\" contenteditable=\"false\" data-width=\"640\" data-height=\"409\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722104439629803_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722104439629803_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722104439629803_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722104439629803_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Dell Q4 Presentation</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">For their CSG business, growth also accelerated from Q3 to 14%. As you can see above, commercial activity seems to be strengthening, and consumer activity looks like it is stabilizing at this point. Margin performance for the past few quarters has been unfavorable, and Q4 was no exception. As mentioned earlier, this could be a sign that clients are choosing lower margin products as overall spending remains weak in the U.S. and in other key markets around the world. This could also be a reflection of the memory shortage causing higher costs for Dell.</p> <p class=\"paywall-full-content\">Just today (Feb. 27th), Preeti Singh of Seeking Alpha <a href=\"https://seekingalpha.com/news/4558735-tech-firms-margins-under-pressure-from-rising-memory-costs\">came out with a piece</a> that described memory-related margin pressure for tech firms. Furthermore, <a href=\"https://seekingalpha.com/news/4558694-pc-smartphone-market-to-see-a-challenging-2026-amid-memory-shortage-rising-prices\">it was reported that</a>, according to research firm IDC, 2026 will be a \"challenging year\" for PCs and smartphones due to the memory shortages. We'll take a look at their guidance next to see what Dell thinks about these risks, but I would say there are definitely some potential headwinds for CSG.</p> <h2 class=\"paywall-full-content\">Outlook Is Respectable</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722110403933597_origin.png\" rel=\"lightbox\" data-width=\"1364\" data-height=\"558\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722110403933597_origin.png?io=w640\" alt=\"Guidance\" width=\"640\" height=\"262\" contenteditable=\"false\" data-width=\"640\" data-height=\"262\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722110403933597_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722110403933597_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722110403933597_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722110403933597_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Dell Q4 Presentation</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">Dell provided both quarterly and annual guidance. We'll focus on the full year numbers for a better long term view of where things are headed. Firstly, for revenue, they see ~23% of growth YoY. This bests FY2026's 19% top line growth rate, and so business activity is set to continue accelerating moving forward.</p> <p class=\"paywall-full-content\">You can see in their key assumptions that ISG is expected to see growth in the mid-40s, while CSG is expected to see growth of just 1% YoY. This would be acceleration for the former but deceleration for the latter, and so it does seem that the memory shortage could be a significant factor moving forward.</p> <p class=\"paywall-full-content\">Dell expects their expense control to remain solid as non-GAAP operating expenses are projected to grow in just the low single digits. This is very strong efficiency, given that the revenue growth rate will be above 20%.</p> <p class=\"paywall-full-content\">Lastly, for adjusted EPS, they see growth of ~25%. While this is a modest slowdown from FY2026, note that it still outpaces the expected top line growth rate for FY2027 as an indication of respectable profitability moving forward. As a whole, I consider their annual outlook to be solid and note that they <a href=\"https://seekingalpha.com/news/4558194-earnings-snapshot-dell-guides-fq1-fy27-comfortable-above-estimates-after-solid-quarterly-print\">guided far above consensus</a> for both the top and bottom line.</p> <h2 class=\"paywall-full-content\">Valuation Gets Even Cheaper</h2> <p class=\"paywall-full-content\"><figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722116131040013_origin.png\" rel=\"lightbox\" data-width=\"887\" data-height=\"820\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722116131040013_origin.png?io=w640\" alt=\"Valuation\" width=\"640\" height=\"592\" contenteditable=\"false\" data-width=\"640\" data-height=\"592\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722116131040013_origin.png?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722116131040013_origin.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722116131040013_origin.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/57947294-17722116131040013_origin.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Seeking Alpha</span></p></figcaption></figure></p> <p class=\"paywall-full-content\">In my previous article, I stated that their valuation was very cheap. That was when the forward P/E ratio was at a reading of 12.16. As you can see <a href=\"https://seekingalpha.com/symbol/DELL/valuation/metrics\">in the table above</a>, this multiple has further retreated to a current level of just 10.57. In my view, this shows that Dell stock is very attractively valued. You can also see above that Dell is trading at levels far below the IT sector median for nearly all multiples, and so I would say the market isn't giving them enough credit.</p> <p class=\"paywall-full-content\">Firstly, Dell's fundamentals aren't perfect. Margin weakness in ISG hints at commoditization risks, while the memory shortage is a potentially significant headwind for CSG moving forward. Despite these challenges, there is no denying that AI demand is more than robust and that their growth is overall accelerating. Business activity is strong, and the company's good control of operating expenses is helping to offset gross margin weakness. Therefore, as a whole, Dell remains in a solid position moving into FY2027.</p> <p class=\"paywall-full-content\">In my view, the valuation multiples above show that the stock is undervalued relative to the company's fundamentals and prospects, and so the risk/reward remains very attractive at current levels.</p> <h2 class=\"paywall-full-content\">Takeaway</h2> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">As stated in the intro, I expressed my view that Dell was approaching bargain territory in my previous article. After today's analysis and review of their Q4 earnings results, I believe the stock is now deep in bargain territory. Sure, there were weak points and risks pointed out in this article, but at this valuation, the market is underpricing and underappreciating what the company brings to the table. AI demand is as solid as ever, and the financials are in good shape overall. With Dell now even cheaper than in my previous article, according to the forward P/E ratio, I have decided to upgrade the stock to a Strong Buy rating.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238577123/image_2238577123.jpg",
            "link": "https://seekingalpha.com/article/4876493-dell-is-now-deep-in-bargain-territory-rating-upgrade",
            "pub_date": "2026-02-28 03:55:54",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876524",
            "title": "Wall Street Roundup: Nvidia Beats And Drops In Edgy Market",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w630\" alt=\"Nvidia Corporation building in Taipei, Taiwan.\" data-id=\"1412721464\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">BING-JHEN HONG/iStock Editorial via Getty Images</p></figcaption></figure><div class=\"inline_ad_placeholder\"></div></p> <p>Listen below or on the go on <a href=\"https://podcasts.apple.com/us/podcast/wall-street-breakfast/id1358381502\" rel=\"nofollow\">Apple Podcasts</a> and <a href=\"https://open.spotify.com/show/05uLjJxkVgQsRk8LWLCLpx?si=r3_yJgxiQiivJwNQG8WNew&amp;nd=1\" rel=\"nofollow\">Spotify</a></p> <p><div class=\"pcast hidden-print\">\n  <div class=\"pcast__section-1\">\n    <img alt=\"\" class=\"pcast__top-img pcast__marketing\" src=\"https://static.seekingalpha.com/uploads/2018/11/21/podcast_series_header.png?io=w640\" loading=\"lazy\">\n  </div>\n  <div class=\"pcast__section-2\"><iframe src=\"https://widget.spreaker.com/player?episode_id=70340235&amp;theme=light&amp;playlist=false&amp;playlist-continuous=false&amp;chapters-image=true&amp;episode_image_position=right&amp;hide-logo=true&amp;hide-likes=true&amp;hide-comments=true&amp;hide-sharing=true&amp;hide-download=true&amp;color=ff6900\" width=\"100%\" height=\"200px\" title=\"Wall Street Roundup: Nvidia beats and drops in edgy market\" frameborder=\"0\" sap-id=\"4\"></iframe></div>\n  <div class=\"pcast__section-3\">\n    <div class=\"pcast__ad-container\"></div>\n  </div>\n</div>\n</p> <p>Is Nvidia in a trap of its own making? (0:25) Microsoft, IBM, Salesforce and AI moats (2:30) Week's biggest movers (8:00) Netflix bows out; Paramount and Warner Bros closer to deal (10:20)</p> <p>Transcript</p> <p><strong>Rena Sherbill: </strong>Our last Wall Street roundup of February. Welcome back, Brian Stewart, Seeking Alpha's Director of News.</p> <p><strong>Brian Stewart:</strong> Great to be here.</p> <p><strong>Rena Sherbill: </strong>Talk to us, what are you looking at these days?</p> <p><strong>Brian Stewart:</strong> I think we have to start with Nvidia (<a href=\"https://seekingalpha.com/symbol/NVDA\" title=\"NVIDIA Corporation\">NVDA</a>). The stock dropped about 5% yesterday after its earnings report. It was up initially in the post market, but then eventually ended the next day lower. Beat expectations, gave better expected guidance. On the surface, everything seemed fine.</p> <p>I think in terms of explaining why it's down, I think I would point listeners to a <a href=\"https://seekingalpha.com/article/4872493-this-is-a-stock-pickers-market\">conversation</a> that you had last week on Investing Experts.</p> <p>There was a good discussion about whether Nvidia might be kind of in a trap of its own making where even good results are never going to be good enough because there's just sort of this built in expectation that Nvidia is going to blow us away every time they report results.</p> <p>So I think it's really a sell on the news kind of situation. The stock was up six out of the seven days going into earnings. So there was this building anticipation for it. I think everybody thought results were fine, better than fine.</p> <p>But the narrative about the build out for AI infrastructure remains in place. There's no end in sight to the amount of money that these companies seem willing to spend in terms of buying chips. think really from a video's point of view, it's almost like a supply problem.</p> <p>I think filling all the demand that's out there is probably getting a little difficult. But when you look at the broader market, the stock has been in a range pretty much this entire year since November, really. So you're just having trouble for Nvidia, for investors to see the next step for Nvidia.</p> <p>And creates a situation where there's sort of this worry that the other shoe is going to drop eventually. Like if they ever kind of have a bummer quarter, you know, the stock might feel it pretty sharply.</p> <p><strong>Rena Sherbill: </strong>We'll leave a link to that Investing Experts episode. There's actually a couple in the past week that we discussed that conundrum of Nvidia. I'm going to leave a <a href=\"https://seekingalpha.com/article/4874186-why-daily-stock-picks-gary-vaughan-likes-large-cap-tech-and-energy\">link</a> to both. What else are you looking at stock wise?</p> <p><strong>Brian Stewart:</strong> Yeah, I think a lot of headlines this this week kind of played into the the conversations surrounding AI, like all the different facets of it. The market was kind of dinged after the Nvidia earnings, the sort of overall response to it.</p> <p>But it wasn't anything major. I think of it as like a jump scare in a horror movie. Most of the time when there's a jump scare, it's one of the cats jumping out in front of you. The worry is that eventually one day it'll be a monster in the closet that jumps out. So I just think that the market is on edge.</p> <p>As we integrate the AI revolution into our conceptions of what the economy looks like, it's just gonna be a long-term process and there's really no way to sort of game it out in any sort of way where you could be confident about your model of what's gonna happen is correct.</p> <p>Just some examples, (<a href=\"https://seekingalpha.com/symbol/IBM\" title=\"International Business Machines Corporation\">IBM</a>) was down 13 % on Monday. Biggest drop for the company since 2000. it's not about 20 % in the past month. So it was already showing some weakness before, it was dropped. The catalyst for that was Anthropic saying that Claude can improve COBOL, which is IBM's proprietary programming language. The response to that from IBM and from defenders is, it's one thing to kind of be able to emulate these proprietary languages and quite another to use them in the way that they're designed to be used.</p> <p>There's just several more steps of it. I saw Dan Ives have a comment about the fears around software and AI kind of taking over the software space. And he basically said that even if you can replicate the software, you still don't have the corporate shell around it.</p> <p>You take a company like Microsoft (<a href=\"https://seekingalpha.com/symbol/MSFT\" title=\"Microsoft Corporation\">MSFT</a>) and Word and Excel and things like that, you can get free or cheap spreadsheet software elsewhere. You can get free or cheap word processing software elsewhere, but the connections that Microsoft has, the reach it has, the brand it has makes it more valuable. Unless everybody's just gonna vibe code their own spreadsheet software, there's still a market for Excel.</p> <p>And I think that's true. If you think about, you could go to the store and buy your generic, my grocery store is Wegman. So you can get like W Cola or whatever it's called. But people still want Coke, you know? And so I think that that's a pretty good argument for some of these larger companies.</p> <p>The moat might be different than what people are imagining that moat to be. But it doesn't speak well for smaller companies that don't have that sort of brand identity and don't have that reach. You might have sort of big monoliths at the sort of top of the market. And then like a lot of little fish kind of swimming around elsewhere. And again, that's something that the economy in general is going to work out over the next few years.</p> <p>And then on that same topic, we had Salesforce (<a href=\"https://seekingalpha.com/symbol/CRM\" title=\"Salesforce, Inc.\">CRM</a>) report its earnings this week. It was up about 4 % after reporting earnings. It's still down 27 % yield year to date. So you're basically seeing kind of a relief rally. Things aren't as bad as we had feared. It actually pretty solid earnings report.</p> <p>Salesforce is a company that's become one of the names that people point to for the idea that eventually AI is going to kind of get rid of all these software companies. And I think there's sort of a feeling in the market that that might've been overdone, that we've probably kind of taken that a little too far.</p> <p><strong>Rena Sherbill: </strong>To your point about Microsoft and Excel and its prevalence in the marketplace, I was listening this morning to a couple stories about how in Europe, I believe France recently in some, I don't know if it's national or regional, the government agencies in some districts are stepping away from Teams and Zoom (<a href=\"https://seekingalpha.com/symbol/ZM\" title=\"Zoom Communications, Inc.\">ZM</a>).</p> <p>Other places in Europe are stepping away from using Microsoft and getting out of the dependence on US big tech. Have you heard any stories like this?</p> <p><strong>Brian Stewart:</strong> Well, the one thing would point out is Zoom was down very sharply after its earnings. I was kind of looking at it in the same frame as, you know, if we're if a lot of this software is going to become sort of generic sized, you know, whatever. mean, you can get a lot of video conferencing software that isn't Zoom and, you know, places like Google Meet (<a href=\"https://seekingalpha.com/symbol/GOOG\" title=\"Alphabet Inc.\">GOOG</a>) (<a href=\"https://seekingalpha.com/symbol/GOOGL\" title=\"Alphabet Inc.\">GOOGL</a>), like a lot of a lot of these bigger companies have these items built into it. Not really having much of opinion on the kind of politics of it, the regional aspect of whether people are choosing against America elsewhere. But I do think there are a lot of choices, like a lot of the stuff nobody really cares. Like the Coke, generic Coke kind of controversy, those at least taste different. But I don't know that I would notice if I was using a non zoom zoom like product.</p> <p>So I do think that there are challenges for these companies to build that brand, to build that understanding, to have features that are unique to it, something proprietary, something they can point to that, can kind of prevent what you're discussing is, you have this glut of choice. Whatever reason you might have, whether you don't like the country that the company's based in, if it's too expensive, whatever issue is sort of driving you to look for alternatives, I think there's a lot of alternatives.</p> <p><strong>Rena Sherbill: </strong>Yes, we saw a couple names jump this week, sort of significantly, Circle (<a href=\"https://seekingalpha.com/symbol/CRCL\" title=\"Circle Internet Group, Inc.\">CRCL</a>) being one of them fairly significantly, post earnings, (<a href=\"https://seekingalpha.com/symbol/XYZ\" title=\"Block, Inc.\">XYZ</a>) announced layoff situations. Would you point to those as two of the bigger movers this week?</p> <p><strong>Brian Stewart:</strong> Yeah, Circle jumped 35 % after its earnings. I think, again, like kind of taking it as like another aspect of sort of the overall AI conversation. The Coinbase (<a href=\"https://seekingalpha.com/symbol/COIN\" title=\"Coinbase Global, Inc.\">COIN</a>) CEO had said, I think it was last week after their results that he sees stable coins becoming kind of the central default currency choice for AI agents that was played out a little bit in circles earnings just in the fact that they're stable coin, like the adoption was like strong growth in that area.</p> <p>So I do think that a lot of that upswing wasn't really a response to the earnings per se, which were strong, but not really 35 % increase in stock price strong. But I think it's more just sort of a bet that as we become more reliance on AI agents, you know, like if we're going to have an AI agent that, you know, pays my mortgage, so I don't have to remember it or whatever.</p> <p>It might become, stable coins that become the currency kind of moving back and forth instead of having my AI agent being able to log into my bank account, which seems really dangerous. But there's a pool of stable coins that I have that it can use to do those transactions for me.</p> <p>So I think there's a vision of the future where everyone's always pointed to crypto, this digital currency will be breaking down barriers and providing a less frictionless or more frictionless commerce situation. And for a long time, it's been sort of argued that Bitcoin (<a href=\"https://seekingalpha.com/symbol/BTC-USD\" title=\"Bitcoin USD\">BTC-USD</a>) would be the eventual winner in that.</p> <p>And I think there's a feeling like stable coin is another contender for that category that that might become a default, like actual currency, like a currency that we use. So it doesn't replace the fiat currency, but just kind of becomes a way to facilitate transactions digitally.</p> <p><strong>Rena Sherbill: </strong>And filing this one also under the theme of as the world turns the news out of the movie streaming future of movie conversation with the Paramount (<a href=\"https://seekingalpha.com/symbol/PSKY\" title=\"Paramount Skydance Corporation\">PSKY</a>) Netflix (<a href=\"https://seekingalpha.com/symbol/NFLX\" title=\"Netflix, Inc.\">NFLX</a>), Warner Brothers (<a href=\"https://seekingalpha.com/symbol/WBD\" title=\"Warner Bros. Discovery, Inc.\">WBD</a>) conversation partnership. Netflix has bowed out.</p> <p>It's still not a done deal. I would also point to another Investing Experts <a href=\"https://seekingalpha.com/article/4855483-there-is-no-streaming-war\">conversation I </a>had a couple months ago with Dan Rayburn, who is truly a capital E expert on the space and talking about there is really nothing to talk about until the deal is signed. There's a lot of succession like plot points afoot, I think. But it does seem like Paramount is going to get that deal barring regulation interference.</p> <p>Anything to add there?</p> <p><strong>Brian Stewart:</strong> Yeah, I do think in a way it's better as kind of theater than, the business aspect of it. I have to admit that I've kind of a romantic notion of Warner Brothers, like going back to AOL and even before that.</p> <p><strong>Rena Sherbill: </strong>I don't think you're alone. I think there's a lot of romanticism around that name.</p> <p><strong>Brian Stewart:</strong> Yeah, it just like it keeps getting packed like there's been 100 deals. I mean, I'm exaggerating, but there's there's been it feels like every couple of years, there's a deal with Warner Brothers where it's moving to a new asset. So I just look forward to 2035 when it's open, I Warner Brothers and, you know, like Bugs Bunny is doing my taxes for me or whatever.</p> <p><strong>Rena Sherbill: </strong>And Rita Hayworth is walking down a hologram red carpet and we're back to the old glamour.</p> <p><strong>Brian Stewart:</strong> Yeah, that sounds great. Like you could cast like literally anybody in the history of movies into your movie. It's like if Katherine Hepburn is perfect for this role, let's just cast her. I mean, I think that kind of goes back to what we were talking about, about like the Coke, generic Coke kind of situation with AI. I mean, there'll be a time in the not too distant future where I could make a movie with starring Tom Cruise and Rita Hayworth or whoever.</p> <p>But can I get that in theaters? I mean, obviously there's copyright issues or whatever, but I'm just saying there are value to having the distribution and you know the know how and all the things that go into just being a movie studio versus you know, like if you shoot it on your iPhone because you know the story of the last. I don't know 40 years is it's gets kind of cheaper and cheaper to to make a movie. You know you and your friends can use your iPhone and make a movie that looks pretty close to a movie you know which wasn't that.</p> <p>That wasn't really possible in like, say, 1965 or whatever. Meanwhile, the movies produced by studios get more and more expensive because they're leaning more on the IP and stars and just, you you really have to get attention.</p> <p>So I think like that kind of points where we're talking about the. You know, a world where there's there's a few giant companies in any given space, but then you have a lot of kind of smaller startup situations going on.</p> <p>And then just to go back, like you had mentioned Block (<a href=\"https://seekingalpha.com/symbol/XYZ\" title=\"Block, Inc.\">XYZ</a>), which we didn't talk about too much, but I do think it's one of the more interesting stories of the week.</p> <p>So they had earnings, which were fine, but then they announced a 40 % job cut. I think it's important to note that 40 % is a lot, that's not like a normal corporate, like we're kind of moving deck chairs around, like when a one drug development company misses a primary endpoint on a clinical trial and then they announced they're cutting 40%.</p> <p>But the company made clear that they're doing this because they think AI they're for do as intelligence tools, but I think we're talking AI makes all their workers so much more productive that they really don't need these extra workers. So I think that they're trying to show like that we're a healthy company. We have revenue growth, we have profitability, but we also see a future where we just don't need as many people to do what we want to do. And I think that plays out.</p> <p>One of the interesting aspects of it is the severance packages that they announced were really generous. So it was 20 weeks plus one week per year of tenure, six months of healthcare. The laid off employees get to keep their corporate devices and they also get sort of a $5,000 just bonus to spend as they see fit during their job search. And I don't want to disparage the humanity of the management there. I'm sure that they wanted people to have a smooth transition just because that's the right thing to do.</p> <p>I think from a corporate point of view, you're trying to discover a business reason for giving such generous severance, I think it's to signal to the market that this isn't a panic move.</p> <p>I think it points to the broader social conversation that we're going to have in the future. If AI does make work so efficient that suddenly we have this sort of structurally higher unemployment just because we don't need as many workers. And I'm talking white collar workers, than we once needed, and whether or not that's going to point to a situation where we're to have to have a kind of a different sort of social policy surrounding that.</p> <p>I think Block is sort of saying, if we're going to make these transitions, we have to think about what that means for the individuals involved and not just cut them loose.</p> <p><strong>Rena Sherbill: </strong>Anecdotally, I've also seen, I think it's important to point out that we are in the beginning slash midst of this AI changeover of society and how work exists and how it's performed. I've heard anecdotally from a number of people at a number of publicly traded companies and non-publicly traded companies that there were a lot of layoffs because AI has enabled that to happen, but then a lot of those, maybe not a lot, but a good portion of those people have been rehired because management realized there might be some efficiencies, but they don't work out because they don't exactly equal one whole person's, you know, acumen and life experience and ability to really trouble, all the things that we know that humans are capable of.</p> <p>AI can't solve for all of that, like the business will suffer without long-term corporate know-how and all the things that humans provide. So I think there is genuine fear and also genuine planning for this change for obvious reasons. But I think also we are still in the TBD phase of this. We don't really know how this is. It's certainly significantly going to change things. But I think long-term, we're still not sure, I would say.</p> <p><strong>Brian Stewart:</strong> Yeah, well, I mean, you make a good point because the other side of the argument, I don't know if you call it like the libertarian side or whatever, would be that the the increase in productivity makes every employee more profitable, you know, because you get more out of them.</p> <p>So you actually want more employees because each employee becomes that much more of a profit generator as long as you can kind of usefully employ them. I think that's another model that's possible. And I think that's an argument that people would make is okay. You might see a blip of this layoff round. But as AI works its way through the population, you're just going to get a situation where you're going to need more people.</p> <p>And that's been the argument in going from sort of a manufacturing economy in sort of pre-1970s kind of timeframe to a more service economy. And the argument is that the economy always kind of finds a place for people to be useful. We went from working in factories to coding and now we're going to go from coding to, you know, prompt writing or however you want to envision the future. So I do think you're right. There's a bunch of different possibilities as we sort of branch off into the next time.</p> <p><strong>Rena Sherbill: </strong>And there is always a chasm between the promise of a thing and the delivery of a thing. So a lot to keep in mind as the days and years unfold. What are you looking at earnings wise in the coming week?</p> <p><strong>Brian Stewart:</strong> So not lot of major headliners. You have some retailers coming next week. You got Macy's (<a href=\"https://seekingalpha.com/symbol/M\" title=\"Macy's, Inc.\">M</a>), got Best Buy (<a href=\"https://seekingalpha.com/symbol/BBY\" title=\"Best Buy Co., Inc.\">BBY</a>), American Eagle (<a href=\"https://seekingalpha.com/symbol/AEO\" title=\"American Eagle Outfitters, Inc.\">AEO</a>). You also have a few tech players.</p> <p>Alibaba (<a href=\"https://seekingalpha.com/symbol/BABA\" title=\"Alibaba Group Holding Limited\">BABA</a>) is the kind of highlight there, also Broadcom (<a href=\"https://seekingalpha.com/symbol/AVGO\" title=\"Broadcom Inc.\">AVGO</a>). So I don't think there's gonna be anything market moving in terms of the S&amp;P (<a href=\"https://seekingalpha.com/symbol/SP500\" class=\"ticker-link\">SP500</a>) or the NASDAQ (<a href=\"https://seekingalpha.com/symbol/NDAQ\" title=\"Nasdaq, Inc.\">NDAQ</a>) or whatever, but within particular sectors and particular companies we are gonna get some information.</p> <p>And then along with the conversation that we've been having, the jobs data is due out next week as well. So we're gonna get an update on the macro impact of, like you said, a bunch of these companies deciding whether or not they need as many employees as they used to think they did.</p><div class=\"before_last_paragraph-piano-placeholder\"></div><p>Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412721464/image_1412721464.jpg",
            "link": "https://seekingalpha.com/article/4876524-wall-street-roundup-nvidia-beats-and-drops-in-edgy-market",
            "pub_date": "2026-02-28 03:46:33",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876486",
            "title": "NexPoint Residential Trust: 2026 Outlook Reflects Multiple Headwinds (Upgrade)",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://media.gettyimages.com/id/2229925234/photo/suburban-florida-residential-complex-with-modern-condominiums-and-landscaped-surroundings.jpg?b=1&amp;s=612x612&amp;w=0&amp;k=20&amp;c=Gy5JgllOOGMhwsSIplS0FnGfEaL8INvKkBSTESSp5jM=\" alt=\"Suburban Florida residential complex with modern condominiums and landscaped surroundings, illustrating U.S. housing trends\" data-id=\"2229925234\" data-type=\"getty-image\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Bilanol/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <h2>Introduction</h2> <p>After a lackluster performance in 2025, my hopes were that U.S. residential REITs such as NexPoint Residential Trust, Inc. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/NXRT\" title=\"NexPoint Residential Trust, Inc.\">NXRT</a></span>) would finally stage a turnaround in 2026. Alas, despite a notable decline in 10-year U.S. treasury<span class=\"paywall-full-content\"> yields (</span><a href=\"https://seekingalpha.com/symbol/US10Y\" class=\"ticker-link paywall-full-content\">US10Y</a><span class=\"paywall-full-content\">) to around 4% and solid performance for the broad Vanguard Real Estate Index Fund ETF (</span><a href=\"https://seekingalpha.com/symbol/VNQ\" title=\"Vanguard Real Estate Index Fund ETF\" class=\"paywall-full-content\">VNQ</a><span class=\"paywall-full-content\">), NXRT is down in the mid-single-digits year-to-date.</span></p> <p class=\"paywall-full-content\">While the company's 2026 outlook reflects continued operating performance pressure and well-known refinancing headwinds, I think that the shares may finally catch a bid later this year, thus upgrading the rating to Strong Buy. My bullish outlook is underpinned by:</p> <ul class=\"paywall-full-content\"> <li>An undemanding 11.2x 2026 Core FFO multiple, notwithstanding the company's high leverage.</li> <li>An attractive 6.7% market-implied cap rate, notably above management estimates used to calculate a midpoint net asset value of $48.57/share.</li> <li>The potential for near-term catalysts such as asset sales and Fed rate cuts in H2 2026.</li> </ul> <p class=\"paywall-full-content\">Readers not familiar with NXRT may find the <a href=\"https://seekingalpha.com/article/4847005-nexpoint-residential-trust-risks-tilted-to-upside-heading-into-2026\"><em>Company Overview</em> section in my previous article insightful</a>. The only major change I would highlight is that NXRT acquired a Las Vegas property for $73 million in December 2025, bringing its enterprise value to $2.3 billion as of February 2026, 68% of which is funded with net debt.</p> <h2 class=\"paywall-full-content\">Q4 2025 Results Overview</h2> <p class=\"paywall-full-content\"><a href=\"https://s26.q4cdn.com/937656400/files/doc_financials/2025/q4/NXRT-Q4-2025-Earnings-Release-FINAL.pdf\" rel=\"noopener\">NXRT reported Core FFO of $0.65/share</a> in the final quarter of 2025, down 4.4% Y/Y. The decline was principally driven by a 4.8% drop in same-store net operating income [NOI], only partially offset by a 2.9% reduction in shares outstanding.</p> <p class=\"paywall-full-content\">The decline in NOI came as NXRT ended 2025 with an occupancy of 92.7%, 2% lower Y/Y, with the company seeing rents largely flat Y/Y at $1,489/unit.</p> <p class=\"paywall-full-content\">Relative to Q3 2025, we observe that NOI dynamics deteriorated notably (NXRT had recorded NOI growth of 3.5% relative to Q3 2024), with occupancy slipping 0.9% Q/Q as well.</p> <p class=\"paywall-full-content\">As such, it is fair to say NXRT ended a challenging 2025 on a weak footing, although share repurchases and stronger performance early in the year helped the company deliver full-year 2025 Core FFO of $2.79/share, flat relative to 2024.</p> <h2 class=\"paywall-full-content\">2026 Outlook</h2> <p class=\"paywall-full-content\">The weak year-end performance is reflected in the company's 2026 Core FFO outlook of about $2.57/share (range of $2.42-2.71), implying a drop of roughly 7.9% Y/Y. The principal driver behind the decrease will be higher interest costs, while NOI is seen at about $155 million, only down 0.5% on a same-store basis.</p> <p class=\"paywall-full-content\">As <a href=\"https://seekingalpha.com/article/4874043-nexpoint-residential-trust-inc-nxrt-q4-2025-earnings-call-transcript\">discussed on the conference call</a>, NXRT's average cost of debt stood at 3.28% at year-end 2025, below recent financing achieved at a spread of 1.23% relative to the 30-day average secured overnight financing rate [SOFR]. With Fed funds futures <a href=\"https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html\" rel=\"nofollow\">pricing in</a> a Fed funds rate of about 3% by the end of 2026, we see that the company's marginal financing cost should be slightly above 4% at the end of this year.</p> <p class=\"paywall-full-content\">To sum up, NXRT's 2026 outlook principally reflects the gradual expiration of favorable interest rate swaps (an effect that will likely continue to weigh on Core FFO in 2027) as well as some incremental decline in net operating income.</p> <h2 class=\"paywall-full-content\">Valuation and Rating</h2> <p class=\"paywall-full-content\">NXRT trades at only 11.2x its Core FFO outlook for 2026. I think this low multiple is principally the result of the REIT's high leverage (68% net debt relative to enterprise value), as well as continued pressure on Core FFO from a challenging operating environment and higher financing costs.</p> <p class=\"paywall-full-content\">In light of the REIT's high indebtedness, looking at enterprise-level valuation metrics, such as the market-implied cap rate, may provide a clearer picture. This is especially true in light of ongoing refinancing at higher rates, the impact of which partially depends on the speed of future Fed rate cuts (hence is somewhat difficult to estimate). As a reminder, enterprise-level valuations are agnostic between cash flows to shareholders and debt holders, making them particularly useful in NXRT's case.</p> <p class=\"paywall-full-content\">NXRT expects 2026 NOI of about $155 million, or a market-implied cap rate of 6.7% relative to the $2.3 billion enterprise value. While the anticipated 0.5% NOI decline in 2026 naturally puts near-term pressure on total return prospects, over the medium to long term, I anticipate NOI growth to return to a level close to the 2% inflation rate.</p> <p class=\"paywall-full-content\">The 6.7% is also notably above the 5.25-5.75% cap rate range used by the company to estimate a <a href=\"https://s26.q4cdn.com/937656400/files/doc_financials/2025/q4/NXRT-Esupp-Q4-25-FINAL.pdf\" rel=\"nofollow\">net asset value</a> [NAV] of $48.57/share, reflecting a range of $41.43-55.72/share depending on the cap rate used.</p> <p class=\"paywall-full-content\">As of the time of writing, NXRT trades marginally below $29/share, reflecting significant double-digit upside to net asset value estimates. Investors will pay close attention to potential disposals later in 2026, as their cap rates may either confirm management cap rate assumptions or, alternatively, make them seem too optimistic.</p> <p class=\"paywall-full-content\">To conclude, taking account of my expectations for a gradual improvement in operating performance in 2027, fading refinancing headwinds thanks to anticipated Fed rate cuts (a trough in Core FFO will likely be reached in 2027), and attractive enterprise-level valuation, I now believe that a Strong Buy rating is warranted for NXRT, up from my previous Buy rating.</p> <p class=\"paywall-full-content\">Near-term catalysts may include asset sales close to management estimates of net asset value, as well as the first rate cut for 2026, which markets price in for June/July 2026.</p> <h2 class=\"paywall-full-content\">Risks</h2> <p class=\"paywall-full-content\">In light of NXRT's elevated leverage, a slower-than-expected pace of Fed rate cuts will likely put further pressure on refinancing costs in 2026-2027. As such, even if operating performance does improve next year, a further reduction in Core FFO cannot be ruled out and, in fact, is quite likely in my opinion, since swap expirations are tilted toward H2 2026 (principally in September 2026).</p> <p class=\"paywall-full-content\">The second key risk to consider is that operating performance fails to pick up in 2027, contrary to the optimism voiced by chief investment officer Matthew McGraner on the <a href=\"https://seekingalpha.com/article/4874043-nexpoint-residential-trust-inc-nxrt-q4-2025-earnings-call-transcript\">conference call</a>:</p> <blockquote class=\"paywall-full-content\"><p>After absorbing the largest supply of wave since the 1980s, completions -- with completions peaking at almost 700,000 units in 2024, a 54% increase from 2021 baseline completions, we are optimistic that new lease growth is set to turn positive across most Sun Belt markets than the second half of this year with sharp acceleration into 2027. Reasons for our belief include persistent structural demand. The cost to own a home is 3x more to rent an apartment in our markets. A 60% decline in new market rate deliveries from the peak and construction starts running approximately 70% below their 2022 peak, locking in a multiyear supply trough. Weighting each NXRT market by unit exposure, the portfolio level to jobs new construction unit ratio bottomed at approximately 1.5 jobs to one unit of new delivery in mid-2025 and our entire portfolio is projected to cross back above the historically significant ratio of 4 jobs to one unit by Q1 of 2027.</p></blockquote> <p class=\"paywall-full-content\">A prolonged period of lackluster NOI growth, with or without refinancing headwinds, will likely result in NXRT stock continuing to trade at a high market-implied cap rate, thus dashing hopes for a quick turnaround in the share price.</p> <h2 class=\"paywall-full-content\">Conclusion</h2> <p class=\"paywall-full-content\">For NXRT, 2026 is starting in the same way 2025 ended, with the REIT's shares significantly underperforming the broader VNQ ETF. While the company's outlook principally reflects refinancing headwinds that were known in advance, expectations for a further NOI decline in 2026 are weighing on the shares, with the REIT now trading at a market-implied cap rate of 6.7%.</p> <p class=\"paywall-full-content\">I expect operating performance to pick up in 2027, which coupled with a resumption in Fed rate cuts in 2026 should allow NXRT stock to rerate higher. Asset sales close to management estimates of net asset value may prove to be a catalyst for the shares, although we have no indication of a pending sale at the moment.</p> <p class=\"paywall-full-content\">NXRT's high leverage is a key risk in the investment case. Furthermore, a slower pace of operational improvement may further weigh on Core FFO in 2027, which I expect to decline relative to 2026 due to the full-year effect of 2026 swap expirations.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">Thank you for reading.</p>",
            "image": null,
            "link": "https://seekingalpha.com/article/4876486-nexpoint-residential-trust-2026-outlook-reflects-multiple-headwinds-upgrade",
            "pub_date": "2026-02-28 03:36:16",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876477",
            "title": "Carter's Gross Margins Show Challenges With Pricing Power",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w630\" alt=\"A 6 month old baby boy smiling, laying on a bed\" data-id=\"1404691658\" data-type=\"getty-image\" width=\"1536\" height=\"1025\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">Catherine Delahaye/DigitalVision via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <p>Carter's, Inc. (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/CRI\" title=\"Carter's, Inc.\">CRI</a></span>) reported <a href=\"https://ir.carters.com/news-releases/news-release-details/carters-inc-reports-fourth-quarter-and-fiscal-year-2025-results\" rel=\"nofollow\">Q4 '25 results</a>, with positive top-line dynamics, growing via higher pricing and traffic, but negative bottom-line dynamics, posting worse gross (tariff) and operating (marketing) margins.</p> <p>The company also provided fairly<span class=\"paywall-full-content\"> challenging guidance for FY26, expecting again to grow (mainly via pricing) but also to close stores, lose gross margins to tariffs, and potentially maintain operating income. Net income will suffer because of more expensive financing.</span></p> <p class=\"paywall-full-content\">When we consider next year's guidance, the company is trading at a P/E of 10x forward. For a clearly challenged name, with no signs of cyclical improvement and very negative secular trends (drop in fertility), I continue to believe the name is not attractively priced and <a href=\"https://seekingalpha.com/article/4833768-carters-top-line-resists-at-the-expense-of-margins-not-worth-15x-earnings\">maintain</a> a Hold rating.</p> <h2 class=\"paywall-full-content\">Q4 '25 Results</h2> <p class=\"paywall-full-content\">Carter's results were not well received by the market, with the name falling as much as 20% intraday after the release.</p> <p class=\"paywall-full-content\">Part of the reason is probably the 2026 guidance (more on this later), but also the lack of results in Q4 '25. The dynamics in Q4 '25 are also repeating into 2026. We could summarize the situation as ok in the top line, bad in the bottom line.</p> <p class=\"paywall-full-content\">Starting with the top line, the reported figure was good because the company grew revenues by ~7.5% (U.S. retail almost 9.5%, wholesale 3.3%, and international 10%).</p> <p class=\"paywall-full-content\">However, under the hood, revenues still show weakness. First, like with many retailers in Q4, Carter had an extra week compared to last year, which added $37 million in sales out of the $66 million increase (<a href=\"https://ir.carters.com/static-files/765784b7-911a-45b4-bd2a-5b1c777ba303\" rel=\"nofollow\">earnings presentation</a> by segment). That means the comparable figure fell to $29 million, or ~3.3%. Then, we need to add that in both US retail and wholesale, the company is starting to add pricing because it needs to pass on the higher costs of tariffs. If costs go up by 5% and the company passes a 5% price increase, then even if sales are up 5%, no new units were sold, and gross profits are flat. Finally, in the International segment, the USD has depreciated against other currencies (mainly MXN and CAD), resulting in FX-driven growth in USD-denominated revenues.</p> <p class=\"paywall-full-content\">Moving to the bottom line is where the real challenges in the top line continue to show. When adjusting for an impairment last year, the company's adjusted operating margin fell 370 bps. The majority of this fall is attributed to gross margins (460 bps YoY), a mix of tariff impact that has not been passed down to customers, and a policy of lower pricing aggressiveness because of the cyclical position of the market.</p> <h2 class=\"paywall-full-content\">2026 Comments</h2> <p class=\"paywall-full-content\">The guidance for 2026 is very similar to the results from 2025. That is, the company expects to grow the top line, but that is not going to translate into more profits.</p> <p class=\"paywall-full-content\">Carter's is expecting to grow LSD to MSD next year, with U.S. retail growing LSD (MSD after accounting for the closure of stores), whereas wholesale and international grow MSD. A big part of this is pricing, as commented on in the company's <a href=\"https://edge.media-server.com/mmc/p/n3gtzup9/\" rel=\"nofollow\">earnings call</a>.</p> <p class=\"paywall-full-content\">The company did not provide specific guidance for gross margins but expected SG&amp;A to be flat in dollar terms and operating income to grow LSD/MSD. This implies that gross margin should be approximately flat. However, this is hard to square with tariffs. The company commented during the call that the impact of tariffs will be between $200 million and $250 million in FY26 (gross, that is, before pricing action), but that it was only $60 million in FY25. A $225 million gross impact on revenues of about $2.8/2.9 billion implies a pre-pricing impact to gross margins of at least 7/8 percentage points.</p> <p class=\"paywall-full-content\">Indeed, Q1 works as an example, with sales expected to be up HSD, but operating income expected to be down more than 60%.</p> <p class=\"paywall-full-content\">To the operating line impact, we have to add the refinancing of fixed-rate bonds in late 2025, which will add $40 million in interest. This will result in EPS down 10/15% for the year (or guided to around $3.25).</p> <h2 class=\"paywall-full-content\">Valuation</h2> <p class=\"paywall-full-content\">Considering the guidance above and that the stock was trading at around $32/34 on the day of the earnings release, it is basically trading at around 10x FY26 guided earnings.</p> <p class=\"paywall-full-content\">As commented in previous posts, Carter's looks very cheap when looking back (the company made close to $8 in EPS during the post-pandemic), but looking ahead, not so much.</p> <p class=\"paywall-full-content\">Not only is the company showing pricing power challenges (otherwise it should be able to pass down tariff costs), but it also faces an outlook of <a href=\"https://www.cbsnews.com/news/us-birth-rate-all-time-low-cdc-data/\" rel=\"nofollow\">lower fertility</a> in the US and in North America that will have a clear impact on its market in less than 2 years from now.</p> <p class=\"paywall-full-content\">Overall, the company continues to represent a \"value trap,\" a name that is optically cheap but with a worsening business (at least for now) where a low multiple gets higher not because P grows, but because E decreases.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">For the time being, I still consider CRI as not opportunistic but will continue to follow the story with interest. I maintain a Hold.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1404691658/image_1404691658.jpg",
            "link": "https://seekingalpha.com/article/4876477-carters-gross-margins-show-challenges-with-pricing-power",
            "pub_date": "2026-02-28 03:25:58",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876472",
            "title": "ETJ: There's Only One CEF That Will Survive A Market Crash",
            "description": "<figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w630\" alt=\"bad day at wall street\" data-id=\"1451361311\" data-type=\"getty-image\" width=\"1536\" height=\"736\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">franckreporter/iStock via Getty Images</p></figcaption></figure><div class=\"inline_ad_placeholder\"></div> <p data-eci=\"true\">Last year, we saw the broader market averages drop into a bear market over a roughly seven-week period from Feb. 19, when President Donald Trump first introduced his tariffs to the world, to April 8, when we finally hit bottom:</p> <figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_65d4168098c2ea0a770c29fb80a3b9c1.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_65d4168098c2ea0a770c29fb80a3b9c1.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_65d4168098c2ea0a770c29fb80a3b9c1.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_65d4168098c2ea0a770c29fb80a3b9c1.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\" title=\"https://ycharts.com\" target=\"_blank\">YCharts</a></figcaption></figure> <p class=\"paywall-full-content\">And though the markets eventually recovered and went on to new all-time highs, imagine how much better off you would have been if you had prepared for bigger drops, even after the early days of last year's pullback.</p> <p class=\"paywall-full-content\">Well, you can get that in one equity CEF that may fall in the early stages of a bear market, but once its S&amp;P 500 put options kick in after a roughly <em>-3%</em> fall, the fund's NAV will hold up like a champ.</p> <p class=\"paywall-full-content\">And that fund is the Eaton Vance <span>Risk Managed Diversified</span> Equity Income CEF (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/ETJ\" title=\"Eaton Vance Risk-Managed Diversified Equity Inc Fd\">ETJ</a></span>), <em>$8.77 current market price</em>. Now, the first thing to know about ETJ is that it's certainly not a bull market fund, but unlike inverse ETFs, ETJ will go UP in a bull market, though it will not capture 100% of the upside.</p> <p class=\"paywall-full-content\">But that's why I say you have to look at ETJ as more of a high-yield bond fund without the risk of holding high-yield bonds in a bear market. What do I mean by that?</p> <p class=\"paywall-full-content\">If you go back to 2008 during the last financial crisis, heavily leveraged fixed-income CEFs fell anywhere from <em>-30%</em> to <em>-40%</em>, just as much as equity CEFs. So don't think being in fixed-income bond funds during a bear stock market will save you.</p> <p class=\"paywall-full-content\">But there was one fund back in 2008 that owned nothing but stocks and actually gained <em>+6.3%</em> vs. <em>-36.8%</em> for the S&amp;P 500 (<a href=\"https://seekingalpha.com/symbol/SPY\" title=\"State Street SPDR S&amp;P 500 ETF Trust\">SPY</a>), <em>$689.30 current market price</em>.</p> <p class=\"paywall-full-content\">And that CEF was ETJ:</p> <figure class=\"sa-widget sa-ycharts paywall-full-content\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_68aff3a655a29991c38a36e5ab484943.png?io=w640\" alt=\"Chart\" width=\"635\" height=\"366\" class=\"sa-ycharts-img\" data-width=\"635\" data-height=\"366\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/saupload_68aff3a655a29991c38a36e5ab484943.png?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_68aff3a655a29991c38a36e5ab484943.png?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/saupload_68aff3a655a29991c38a36e5ab484943.png?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"><figcaption>Data by <a href=\"https://ycharts.com\" rel=\"nofollow\" title=\"https://ycharts.com\" target=\"_blank\">YCharts</a></figcaption></figure> <p class=\"paywall-full-content\">So how did ETJ do it? Well, market prices in CEFs are established by shareholders buying and selling, so a CEF's market price can actually go much higher or much lower than its NAV. And in volatile markets, you can often see CEFs make dramatic moves at market price even if their NAVs aren't moving much at all.</p> <p class=\"paywall-full-content\">And that's what you can get in ETJ. I have no control over ETJ's market price, which is currently at a <em>-7.5%</em> discount to its NAV. But I do know that once the S&amp;P 500 falls <em>-3%</em> or more, ETJ's put options will start to kick in and provide NAV support.</p> <p class=\"paywall-full-content\">Like most of the Eaton Vance option income CEFs, ETJ owns a technology-heavy S&amp;P 500 benchmark portfolio that has the typical top 10 holdings and sectors that look like this:</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/799235-17722022851855159_origin.jpg\" rel=\"lightbox\" data-width=\"1058\" data-height=\"516\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/799235-17722022851855159_origin.jpg?io=w640\" alt=\"ETJ's top holdings and Sectors\" width=\"640\" height=\"312\" contenteditable=\"false\" data-width=\"640\" data-height=\"312\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/799235-17722022851855159_origin.jpg?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/799235-17722022851855159_origin.jpg?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/799235-17722022851855159_origin.jpg?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/799235-17722022851855159_origin.jpg?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Eaton Vance</span></p></figcaption></figure><p class=\"paywall-full-content\">But when you look at ETJ's option sleeves as of Dec. 31, 2025, it becomes very clear why Eaton Vance includes<span class=\"highlighted_text\"> \"<em>risk managed\" </em>in</span> ETJ's title.</p> <p class=\"paywall-full-content\">Here's a snapshot of ETJ's put and call options as of 12/31/2025:</p> <figure class=\"regular-img-figure paywall-full-content\" contenteditable=\"false\"><picture> <span><a href=\"https://static.seekingalpha.com/uploads/2026/2/27/799235-17722024982166865_origin.jpg\" rel=\"lightbox\" data-width=\"772\" data-height=\"662\" data-og-image-twitter_small_card=\"true\" data-og-image-twitter_large_card=\"true\" data-og-image-twitter_image_post=\"true\" data-og-image-msn=\"true\" data-og-image-facebook=\"true\" data-og-image-google_news=\"true\" data-og-image-google_plus=\"true\" data-og-image-linkedin=\"true\" role=\"button\" aria-label=\"Expand image into lightbox view\"><img src=\"https://static.seekingalpha.com/uploads/2026/2/27/799235-17722024982166865_origin.jpg?io=w640\" alt=\"ETJ's option sleeves as of 12/31/25\" width=\"640\" height=\"549\" contenteditable=\"false\" data-width=\"640\" data-height=\"549\" loading=\"lazy\" srcset=\"https://static.seekingalpha.com/uploads/2026/2/27/799235-17722024982166865_origin.jpg?io=w640 640w,https://static.seekingalpha.com/uploads/2026/2/27/799235-17722024982166865_origin.jpg?io=w480 480w,https://static.seekingalpha.com/uploads/2026/2/27/799235-17722024982166865_origin.jpg?io=w320 320w,https://static.seekingalpha.com/uploads/2026/2/27/799235-17722024982166865_origin.jpg?io=w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 180px), 552px\"></a></span> </picture><figcaption><p class=\"item-caption\"><span>Eaton Vance</span></p></figcaption></figure><p class=\"paywall-full-content\">What you see in the notional amounts above is what each option tranche actually protects in ETJ. The written call valuations are what the fund would keep if the tranche expired worthless, whereas the put options will go up in value as the S&amp;P 500 goes down.</p> <p class=\"paywall-full-content\">So if ETJ is a <em>$638 million</em> fund and if you add up the notional values of the written call options and long put options, they each add up to roughly <em>96%</em> of ETJ's total assets managed.</p> <p class=\"paywall-full-content\">That's extremely defensive, especially when the put options go in the money.</p> <p class=\"paywall-full-content\">The final key to understanding ETJ's option sleeves is that its written call options are put on every few business days at <em>+2.1%</em><span class=\"highlighted_text\"> out of the money, while its put options are slightly more out of the money at <em>+3.1%</em>.</span></p> <p class=\"paywall-full-content\">What that means is that ETJ takes in income from selling call options and turns around and buys put options, which are less expensive because they're more out of the money.</p> <p class=\"paywall-full-content\">And because ETJ puts on new option tranches every few days (unlike most option ETFs that use monthly expirations), the fund is always prepared for a sharp drop.</p> <p class=\"paywall-full-content\">It may take a <em>-3%</em> drop in the S&amp;P 500 for ETJ's latest tranche of puts to go in the money, but the more the S&amp;P 500 drops after that, the more of ETJ's put tranches will go in the money too.</p> <p class=\"paywall-full-content\">And this is why ETJ's NAV will not move much once its put options kick in.</p> <h2 class=\"paywall-full-content\"><strong>Conclusion</strong></h2> <p class=\"paywall-full-content\">Again, ETJ's market price can be a lot more volatile than its NAV, but if you're looking for a fund that will eventually hold up in a bear market while paying an <em>+8.9%</em> market yield (annualized) while you wait, then ETJ should be in your portfolio and should be considered more of a safe income fund than an appreciation fund.</p> <p class=\"paywall-full-content\">That said, ETJ is a bit different today than what it was back in 2008. Today, ETJ has more of a growth stock tilt in its portfolio (see top 10 holdings above) than what it had in 2008, which was more overweighted in value stocks.</p> <p class=\"paywall-full-content\">That's because Eaton Vance did want to give ETJ better appreciation potential by including more Nasdaq 100 stocks, even though it uses the S&amp;P 500 as its benchmark and for its options.</p> <p class=\"paywall-full-content\">Recently, though, the Nasdaq 100 has <em>not</em> been outperforming the S&amp;P 500, so that's been a bit of a negative factor for ETJ. But ETJ is still a very forgiving fund at NAV (not necessarily at market price), and even if its portfolio is underperforming the S&amp;P 500, it should be able to deliver a reliable and sustainable high single-digit return, whether it's from its yield, from its appreciation, or a combination of the two.</p> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">And that might look awfully good in case of a bear market!</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1451361311/image_1451361311.jpg",
            "link": "https://seekingalpha.com/article/4876472-etj-theres-only-one-cef-that-will-survive-a-market-crash",
            "pub_date": "2026-02-28 03:16:42",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "4876470",
            "title": "PRA Group: A Better Quarter Is Welcome, But A Lot Of Work Remains",
            "description": "<p data-eci=\"true\"><figure class=\"getty-figure\" data-type=\"getty-image\"><picture> <img src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w630\" alt=\"Time Is Money Concept with Rolled U.S. Dollar Bills and Alarm Clock for Business and Productivity\" data-id=\"2259875657\" data-type=\"getty-image\" width=\"1536\" height=\"1024\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 767px) calc(100vw - 36px), (max-width: 1023px) calc(100vw - 132px), (max-width: 1199px) calc(100vw - 666px), (max-width: 1307px) calc(100vw - 708px), 600px\" fetchpriority=\"high\"> </picture><figcaption><p class=\"item-caption\"> </p> <p class=\"item-credits\">One Punch/iStock via Getty Images</p></figcaption></figure></p> <div class=\"inline_ad_placeholder\"></div> <p>I won’t look a gift horse in the mouth, and PRA Group’s (<span class=\"ticker-hover-wrapper\"><a href=\"https://seekingalpha.com/symbol/PRAA\" title=\"PRA Group, Inc.\">PRAA</a></span>) better-than-expected fourth-quarter results were certainly welcome after another bout of meaningful weakness in the share price. Double-digit growth in revenue and<span class=\"paywall-full-content\"> cash collections were both positive, as was a year-over-year improvement in cash efficiency, but significant performance gaps remain, and management must find ways to improve key yield metrics to drive a sustained recovery in the share price.</span></p> <p class=\"paywall-full-content\">As of Friday morning, PRA Group shares are down about 7% since my last update, with a major post-earnings move helping counter a steep decline in late January. Rival Encore Capital (<a href=\"https://seekingalpha.com/symbol/ECPG\" title=\"Encore Capital Group, Inc.\">ECPG</a>) has done considerably better over that period, and the discrepancy between these two companies across multiple metrics remains stark.</p> <p class=\"paywall-full-content\">The bull argument for PRA Group remains that there is a pool of assets here that can be managed better and generate substantially higher financial returns, and when those improvements come through, they should drive a substantial rerating. The main bearish counterpoint remains the fact that it really is not a “when” and is very much an “if”—there are no guarantees that the new CEO and the latest operational restructuring will meaningfully close what has been a growing operational gap with Encore over several years.</p> <h2 class=\"paywall-full-content\"><strong>A Stronger Fourth Quarter Helps The Turnaround Thesis</strong></h2> <p class=\"paywall-full-content\">I’ll go into the drivers of PRA Group’s current predicament a little later, but suffice it for now to say that the issues here cannot and will not be fixed in a matter of quarters. Even so, good results are good results, and <a href=\"https://ir.pragroup.com/2026-02-26-PRA-Group-Reports-Fourth-Quarter-and-Full-Year-2025-Results\" rel=\"nofollow\">fourth-quarter</a> performance should improve sentiment and confidence around the near-term trajectory of the business.</p> <p class=\"paywall-full-content\">Revenue rose about 15% this quarter, beating expectations by about 13%. Portfolio income (the more reliable revenue driver and the one more tied to core operating performance) rose more than 14%, while expected recoveries rose 16%, helped by 14% growth in excess recoveries.</p> <p class=\"paywall-full-content\">Cash collections grew almost 14% as reported, or about 10% in constant currency. U.S. Core collections rose 19%, while bankruptcy collections were down 7%; the latter can be volatile from quarter to quarter. Core European collections were up 8% in constant currency, while bankruptcy collections were down 23%. Collections from other markets (Brazil, Australia, et al.) were flat in constant currency.</p> <p class=\"paywall-full-content\">Core operating expenses were up only about 4%, helping drive 80bp year-over-year improvement in the cash efficiency ratio to 61.4%. Operating income rose 33%, and PRA Group reported a very large EPS beat relative to sell-side expectations ($1.46 vs. $0.50).</p> <p class=\"paywall-full-content\">Portfolio purchases were down 27% yoy and up 23% qoq, with core US purchases down 37% yoy. Estimated remaining collections were up 15% yoy and almost 3% qoq (to $8.61B), while average receivables rose about 13% yoy and 1% qoq.</p> <h2 class=\"paywall-full-content\"><strong>A Lot Of Work Remains</strong></h2> <p class=\"paywall-full-content\">The fourth quarter was inarguably better than expected, but a look at Encore’s <a href=\"https://encorecapital.gcs-web.com/static-files/e02cfdf1-86f8-4d9c-bfde-7218f8dbd9c3\" rel=\"nofollow\">fourth-quarter</a> performance underscores that there is still a major performance gap here.</p> <p class=\"paywall-full-content\">Encore saw similar year-over-year growth in ERC (up 14%) on lower receivables growth (up 2%), and portfolio revenue rose about 13% on 21% growth in cash collections. Purchases were down 34% yoy, and the amounts purchased by each company were broadly similar ($315M for PRAA and $327M for Encore). Cash efficiency at Encore improved significantly year over year to 57.1%.</p> <p class=\"paywall-full-content\">Where the gaps are really noticeable is in their respective collections and portfolio yields. PRA Group improved its collection yield (cash collections divided by average receivables) by 30bp yoy to 45.9%, while Encore’s rose 280bp to 62%. Portfolio yield (portfolio revenue divided by receivables) improved 30bp to 22.7% at PRA Group and declined 80bp to 35.1% at Encore.</p> <p class=\"paywall-full-content\">I believe these gaps go a long way toward explaining the divergent performances at the two companies and why/how PRA Group has struggled to regain any real traction in earnings growth or market sentiment.</p> <p class=\"paywall-full-content\">There are multiple potential drivers of different yields, including PRA’s larger European business, but the reality is that Encore is better at analyzing charged-off paper for collectability (and paying appropriate amounts) and then also better at collecting on those debts.</p> <p class=\"paywall-full-content\">Although the two companies do not provide readily comparable data about their portfolios, both buy a lot of credit card debt, including substantial amounts where there have been prior collection attempts. To that end, then, I don’t think there are material ongoing differences in the portfolios that explain the difference (I don’t believe PRA necessarily buys riskier paper and takes a “win big/lose big” approach, for instance). I believe Encore is simply better at modeling expected recoveries and/or takes a more conservative approach with those models.</p> <p class=\"paywall-full-content\">I also believe that Encore out-executes in the collections process, including payer segmentation, collector productivity, and collections strategy. PRA Group management has talked recently about making better use of technology, and this could certainly help collections yield through automation, analytics, payer engagement, and settlement strategy.</p> <p class=\"paywall-full-content\">Perhaps counterintuitively, PRA Group’s cost efficiency may actually be a bit of an issue—I don’t have the data to assert this as fact, but Encore may be making better use of legal collections channels (which are more expensive), simply operating with more collections activity intensity, and/or offering more settlements to enhance recoveries. Clearly something is working better for Encore, as they are trouncing PRA Group in portfolio and collections yields despite a less efficient cash cost structure.</p> <h2 class=\"paywall-full-content\"><strong>The Outlook</strong></h2> <p class=\"paywall-full-content\">With the above in mind, the fact that PRA Group has offshored about a third of their U.S. collections activity and cut 115 corporate/overhead positions (for an estimated $20M/year in savings) is nice, but not necessarily going to solve any of the real issues.</p> <p class=\"paywall-full-content\">Put simply, perhaps too simply, PRA Group has to improve its pre-buy analysis of charged-off paper and make sure they’re more accurately modeling collections and paying appropriate prices. They also have to improve their collections efficiency; while there are enough differences in the two companies’ portfolios that the yields may never match (some paper will simply take longer to collect on, for instance), the numbers suggest that PRA simply isn’t managing the collections process as effectively as it needs to—and that’s down to hiring the right people (and keeping them) and having the right technology to monitor and enhance the collections process.</p> <p class=\"paywall-full-content\">Management explicitly mentioned that it was seeing the benefits of improved buying selectivity, and that suggests that recent acquisition vintages will perform better than has been the case in prior years. That’s a good foundation, but the company has to build on it. To that end, I’d note that management’s guidance for portfolio acquisitions in 2026 ($1B-$1.3B) doesn’t suggest much growth, so revenue growth will have to come from enhanced collections efficacy.</p> <p class=\"paywall-full-content\">If PRA Group is turning around, it will still take time for the benefits to show. There’s already evidence that recent acquisitions are performing better, but improved collections efficiency and fundamentally better acquisition strategies will take time to develop, mature, and show up in the numbers.</p> <p class=\"paywall-full-content\">I believe PRA Group could generate better than 20% earnings growth in 2026, and with a good supply of charged-off paper and operational improvements, I think double-digit growth is possible over the next five years, with longer-term core earnings growth in the high single digits. This, too, should support strong double-digit free cash flow growth that will help reduce leverage, continue to fund portfolio growth, and leave some room for further returns of capital to shareholders.</p> <p class=\"paywall-full-content\">Between discounted cash flow and core earnings, I believe fair value is in the $20 to $22.50 range.</p> <h2 class=\"paywall-full-content\"><strong>The Bottom Line</strong></h2> <div class=\"before_last_paragraph-piano-placeholder paywall-full-content\"></div> <p class=\"paywall-full-content\">This company badly needs a steady period of improved execution, and it’s too soon to say if that’s going to happen. If PRA Group can improve its analytics and execution, there is substantial upside here, but that is the consummate “Spartan if.” Management is saying the right things, including embracing more technology in its purchasing and collections process to better leverage years of collected data, but investors have seen this before. The upside potential is meaningful if this is in fact a real turn in the business, but this is a name only suitable for investors who can tolerate high levels of operational/execution risk.</p>",
            "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2259875657/image_2259875657.jpg",
            "link": "https://seekingalpha.com/article/4876470-pra-group-better-quarter-is-welcome-but-lot-of-work-remains",
            "pub_date": "2026-02-28 03:11:34",
            "source": "seekalpha_articles",
            "kind": 1,
            "language": "en"
        }
    ]
}